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Summary 
The Ap-2 transcription factors comprise a family of closely-related sequence-specific 
DNA-binding proteins that play pivotal and non-redundant roles in regulating gene 
expression during development, differentiation, and tumorigenesis. In mammals, five 
members of the Ap-2 family have been identified (Ap-2α-ε). The Ap-2 family 
members share a highly conserved basic DNA-binding domain and a carboxy-
terminal helix-span-helix motif mediating DNA binding and dimerization. The N-
terminus is more divergent although certain critical residues in the transactivation 
domain are conserved. Ap-2δ is considered the most divergent family member 
because within its transactivation domain Ap-2δ lacks those critical amino acids that 
are important for transcriptional activity suggesting that Ap-2δ may interact with a 
different set of coactivators and target genes. 
According to the restricted Ap-2δ expression in posterior and dorsal midbrain, Ap-2δ 
knockout mice exhibited enhanced apoptotic cell death in the posterior midbrain 
resulting in the complete loss of this structure at the newborn state. Affimetrix 
GeneChip technology on RNA from posterior midbrains of wildtype and Ap-2δ-
deficient mice was employed to identify de novo Ap-2δ targets from the posterior 
midbrain region. The set of potential candidates enclosed the transcription factors 
Pitx2, Mef2c, Bhlhb4 and Pou4f3. Moreover, in a luciferase reporter assay, Ap-2δ 
positively mediated activation of the Bhlhb4 and Pou4f3 promoters. This study also 
revealed that Ap-2δ specifically binds to regulatory sites located in the promoter 
regions of the Bhlhb4 and Pou4f3 genomic loci. Electrophoretic mobility shift assays 
(EMSA) confirmed the direct binding of Ap-2δ to an Ap-2δ-specific consensus 
sequence within the Pou4f3 promoter. Consistently, Ap-2δ occupied the promoters of 
Pou4f3 and Bhlhb4 also in vivo as demonstrated with chromatin immunoprecipitation 
(ChIP) assays, identifying these genes as direct targets of Ap-2δ. In addition, Ap-2δ 
ablation resulted in the downregulation of known Pou4f3 target genes in the posterior 
midbrain. In summary, the data presented here denote the regulatory activity of Ap-
2δ on midbrain-expressed transcription factors as essential for the development of 
the posterior midbrain.  
In the second part of this study, the transcription factor Nfatc2 was identified as a 
new binding partner for Ap-2δ using a yeast-two hybrid assay. Nfatc2 is a widely 
expressed, calcium-regulated transcription factor and a key mediator of gene 
transcription. The interaction of Nfatc2 with Ap-2δ was confirmed in in vitro GST 
pulldown assays. Co-immunoprecipitations were used to establish an interaction in 
mammalian cells. Furthermore, both transcription factors co-localized in the nucleus 
after activation of Nfatc2. Quantitative real-time PCR was employed to analyze the 
synergistical action of Nfatc2 and Ap-2δ on downstream targets. The newly identified 
targets Atm, Egr3, and Mtss1 were found to be downregulated after overexpression 
of Ap-2δ and ectopic expression of Nfatc2 in Neuro2a cells. Consistently, 
downregulation of Tcfap2d by siRNA increased transcript levels of these targets 
indicating for the first time that Ap-2δ also exerts a repressive function. Using ChIP 
assays, Atm, Egr3, and Mtss1 were identified as direct targets because Ap-2δ and 
Nfatc2 occupied the promoter of these genes. Taken together, this work 
demonstrates that Ap-2δ together with Nfatc2 can function as a transcriptional 
repressor and plays an important role in the synergistical regulation of neuronal gene 
expression. 
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1. Introduction 
1.1. The family of Ap-2 transcription factors 
The Ap-2 transcription factor family (Ensembl family ENSF00000001105) consists of 
sequence-specific DNA-binding proteins that have been implicated in orchestrating 
gene expression in the process of development, differentiation, and tumorigenesis. 
Using affinity chromatography, Ap-2α was the first identified family member and was 
isolated as a nuclear protein of 52 kDa from HeLa cells (Williams et al., 1988). Up to 
date, five members of the Ap-2 family have been identified in humans and mice: Ap-
2α, Ap-2β, Ap-2γ, Ap-2δ and Ap-2ε which are all encoded by separate genes (murine 
gene names Tcfap2a-Tcfap2e). Homologs of Ap-2 have also been found in other 
species. The single Drosophila melanogaster and the two Caenorhabditis elegans 
Ap-2 proteins show the weakest phylogenetic relationship with vertebrate Ap-2 
transcription factors (for review see (Eckert et al., 2005)). Nevertheless, their 
presence suggests an evolutionary conservation of Ap-2 proteins. 
 
1.1.1. Structure of Ap-2 proteins 
The Ap-2 family members share a common, characteristic domain structure (Fig. 1). 
Highly conserved are a basically charged DNA-binding domain and a carboxy-
terminal dimerization domain. The latter consists of two putative amphipathic alpha 
helices separated by a large intervening span region of approximately 80 amino 
acids. This helix-span-helix motif is characteristic for Ap-2 proteins and, together with 
the basic domain, mediates DNA binding and dimerization (Williams and Tjian, 
1991b). The proline and glutamine-rich N-terminus is less conserved although a PY 
motif and other critical residues in this domain are shared. Due to fine-mutational 
analyses of the human Ap-2α N-terminus, the activation motif was assigned to amino 
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acids 52-107. Within this sequence, fewer than 36 residues are identical or similar 
among the Ap-2 proteins and are therefore thought to play an essential role for 
transcriptional activity (Wankhade et al., 2000). Ap-2δ is considered the most 
divergent family member because within its transactivation domain (TAD) those 
critical amino acids are missing. This suggests that coactivators and target genes 
interacting with Ap-2δ might be distinct from the candidates already known for other 
Ap-2 proteins.  
 
 
Figure 1: Homodimeric domain structure of Ap-2α protein. The transactivation domain (red) 
contains a conserved PY motif (green) and is followed by a basic domain (yellow) and the 
characteristic helix-span-helix motif (blue) that mediate DNA binding and dimerization (Eckert et al., 
2005) . 
 
Homo- and heterodimer formation as well as integrity of the basic region are 
essential for DNA binding (Williams and Tjian, 1991a, 1991b). Ap-2 dimers bind DNA 
at highly conserved GC-rich consensus sequences present in many cis-regulatory 
regions of cellular and viral promoters and enhancers (Imagawa et al., 1987; Mitchell 
et al., 1987; Williams et al., 1988). The sequences 5’-GCCN3/4GGC-3’ and 5’-
GCCN3/4GGG-3’ were shown to be ideal binding sites for Ap-2 transcription factors 
(Mohibullah et al., 1999). However, Ap-2 binding to a 5’-CCCCAGGC-3’ site in the 
SV40 enhancer element demonstrates that Ap-2 proteins can bind GC-rich regions of 
different compositions (Mitchell et al., 1987). Also, isotype-dependent dimers vary 
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considerably in binding site affinities. Zhao et al. (2001) could show that Ap-2δ 
preferentially binds the specific variation of the GC motif 5’-GCCTGAGGC-3’ 
providing the first example of target sequence specificity among the Ap-2 family 
(Zhao et al., 2003).  Therefore, a number of specifically composed Ap-2/DNA 
complexes may be present in tissues depending on the expression of different Ap-2 
isoforms. 
 
1.1.2. Murine Tcfap2 genes 
Expression studies of Tcfap2 genes during mouse embryogenesis revealed that 
Tcfap2a, Tcfap2b, and Tcfap2c show an overlapping expression pattern first detected 
in neural crest cells and their derivatives (Chazaud et al., 1996; Mitchell et al., 1991; 
Moser et al., 1995; Moser et al., 1997). Furthermore, they are coexpressed in many 
structures of the peripheral and central nervous system, facial and limb 
mesenchyme, various epithelia and the extraembryonic trophectoderm. Strikingly, 
Tcfap2d and Tcfap2e expressions deviate from this pattern. Tcfap2d was observed in 
the central nervous system, the retina and the developing heart (Zhao et al., 2003). 
Tcfap2e was detected in neural tissue and cells of the olfactory bulb (Wang et al., 
2004). 
 
1.1.2.1. Ap-2α 
AP-2α was the first characterized family member and was identified as a nuclear 
protein due to its ability to bind to the viral SV40 promoter and the human 
metallothionein IIa promoter (Mitchell et al., 1987).  
Tcfap2a is expressed at day E8.5 in neural folds and head mesenchyme of neural 
crest cell origin. During development, Tcfap2a expression persists in neural crest 
derivatives like the dorsal root ganglion and facial and branchial arch mesenchyme. 
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Appreciable Tcfap2a signals also occur in epidermal ectoderm, limb bud 
mesenchyme, mesometanephric regions, and a lateral portion of the CNS. In adult 
mouse tissue, Tcfap2a mRNA was observed at low levels in the kidney, cerebellum, 
spleen and thymus (Mitchell et al., 1991). Another group also detected Tcfap2a 
expression in adult skin, eye, and prostate (Moser et al., 1995). 
Two groups independently from each other disrupted the Tcfap2a gene in mice by 
targeted mutation of either exon 5 or 6, respectively (Schorle et al., 1996; Zhang et 
al., 1996). These mice had multiple congenital defects and died perinatally. They 
exhibited cranio-abdominoschisis and severe dismorphogenesis of the face, skull, 
sensory organs and the cranial ganglia. A failure of cranial neural tube closure was 
observed between E9 and E9.5. In wildtype animals, neural folds are apposed and 
fused over most of the spinal and cranial region at that time. However, in knockout 
mice, cranial neural folds remained widely separated over their entire rostral-caudal 
axis, resulting in exencephaly. Wildtype and mutant embryos displayed a similar 
staining of migratory neural crest cells indicating that neural crest cells are able to 
migrate and differentiate into derivatives of the facial mesenchyme. TUNEL staining 
revealed coincided increased apoptosis in the trigeminal ganglia and the midbrain, 
anterior hindbrain and proximal mesenchyme of the first branchial arch resulting in 
underdeveloped or missing cranial ganglia (Schorle et al., 1996; Zhang et al., 1996). 
 
1.1.2.2. Ap-2β 
The murine cDNA encoding the second Ap-2 transcription factor, Ap-2β, was first 
cloned and characterized by Moser et al. (Moser et al., 1995). Ap-2β shared an 
overall identity of 76% with Ap-2α and exhibited similar DNA binding and 
transactivation abilities. During embryonic development, Tcfap2b mRNA was 
detected between E11.5 and 17.5. Around E13.5 and E15.5, strong signals for 
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Tcfap2b were observed in many neural tissues especially the midbrain and the spinal 
cord. Expression overlapped with regions of developing sensory neurons. 
Furthermore, Tcfap2b mRNA was detected in facial mesenchyme like the olfactory 
epithelium and the first branchial pouch, and to a lesser extent, also in peripheral 
tissues such as the kidney and skin. Transcript levels decreased significantly after 
birth but were still abundant in the eye, skin, and kidney and at lower levels in the 
prostate, thymus, and brain (Moser et al., 1995). 
Generation of Tcfap2b null mice revealed a role for Ap-2β in programming cell 
survival in renal epithelial cells (Moser et al., 1997). Tcfap2b-/- mice completed 
embryogenesis but died at postnatal days 1 and 2 due to polycystic kidney disease. 
Kidney development occured normally, but at the end of embryogenesis expression 
of bcl-XL, bcl-w, and bcl-2 was downregulated resulting in massive apoptotic death of 
collecting duct and distal tubular epithelia (Moser et al., 1997).  
The autosomal dominant disorder Char syndrome is characterized by patent ductus 
arteriosus, facial dysmorphism and hand anomalies. Char syndrome was linked to 
the genomic critical region on chromosome 6p12-p21 which encodes the human 
TFAP2B gene. Two families inheriting Char syndrome were then analyzed for 
mutations in the TFAP2B gene. Indeed, the substitution of an alanine by aspartic acid 
at codon 264 and the substitution of an arginine by cysteine at codon 289 were 
identified in all affected individuals of the family. These missense mutations altering 
conserved residues were not observed in any unaffected family members (Satoda et 
al., 2000). The protein resulting from the mutations was impaired in its ability to bind 
to a consensus AP-2 target DNA sequence despite proper dimerization. Dimerization 
of mutant with wildtype AP-2β reduced transactivation of gene expression indicating 
a dominant negative mechanism. These findings identified the first genetic cause for 
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Char syndrome and assigned an essential role for AP-2β in ductal, facial and limb 
development (Satoda et al., 2000). 
 
1.1.2.3. Ap-2γ 
The Tcfap2c gene was identified as an immediate-early retinoic acid-induced gene in 
murine P19 embryonal carcinoma cells (Oulad-Abdelghani et al., 1996). Like Ap-2α 
and Ap-2β, the Ap-2γ protein is able to form a complex with the Ap-2 recognition 
sequence GCCN3GGC and activate transcription from an Ap-2 binding site 
containing reporter.  
As early as E7.0, Tcfap2c signals were observed in extraembryonic tissue. Strong 
signals were derived from the lining of the extraplacental cavity and in the chorion as 
well as from trophoblast giant cells (Chazaud et al., 1996). Tcfap2c was also 
expressed in the innermost cells of the decidua. 
At E7.5, Tcfap2c expression was detected in the boundary region between neural 
plate and surface ectoderm. Tcfap2c transcripts were also present in premigratory 
and migrating neural crest cells until E8.5. Moreover, Tcfap2c was expressed in facial 
mesenchyme, limb buds, the presumptive cortical region of the forebrain vesicles and 
the urogenital system (E9.5 – E11.5). Interestingly, Tcfap2c transcripts were 
abundant in primordial germ cells in the genital ridges. However, this expression 
seemed to be transient as mRNA levels could no longer be detected in the fetal ovary 
by E14.5 – E15.5 (Chazaud et al., 1996). Tcfap2c expression in adult mouse tissue is 
clearly tissue-specific because significant signals were only detected in lungs, ovary 
and testis. In addition to that, Tcfap2c is expressed in most squamous epithelia, 
several exocrine glands and in the inner nuclear and ganglion cell layer of the retina 
(Oulad-Abdelghani et al., 1996). 
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To dissect the function of Ap-2γ, Tcfap2c knockout mice were generated. This 
genotype resulted in embryonic lethality and assigns Ap-2γ an essential role during 
early embryogenesis. Ap-2γ deficiency led to reduced proliferation in extraembryonal 
ectoderm and in the ectoplacental cone. As a consequence, the embryo could not be 
sufficiently supplied with nutrients and died (Werling and Schorle, 2002). To 
overcome embryonic lethality, a conditional Tcfap2c mouse mutant was generated 
which enables the spatial and temporal deletion of both Tcfap2c alleles (Werling and 
Schorle, 2002) by circumventing the placenta phenotype. The analysis of those null 
mutants suggests a role for Ap-2γ in germ cell development as Ap-2γ-deficient mice 
were sterile and had lost their germ cells (Weber et al., 2011).  
 
1.1.2.4. Ap-2δ 
The mouse Tcfap2d gene was cloned and characterized by Zhao and collegues in 
2001 (Zhao et al., 2001). During positional cloning studies for Char syndrome on the 
Tcfap2b genomic locus, a novel Tcfap2 gene was identified residing 40 kb from the 3’ 
end of the Tcfap2b gene. The cDNA derived from 8 exons included 1788 bp and 
encoded a protein (designated Ap-2δ) of 452 amino acids that gave an estimated 
molecular weight of 49.5 kDa. This gene was highly homologous to previously 
identified Tcfap2 genes in its DNA binding and dimerization mediating C-terminus but 
differed significantly from other Ap-2 members in the transactivation domain. The PY 
motif and other residues critical for transactivation are not conserved in the Ap-2δ 
transactivation domain. In particular, four residues in the basic binding region which 
are completely conserved among all other Ap-2 proteins differ in Ap-2δ (Asp209, 
Leu210, Lys235, and Ile252).  
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Markus Moser 
 
Figure 2: Tcfap2d expression during development and in the postnatal brain.  
Tcfap2d expression was analyzed using radioactive in situ hybridization with a Tcfap2d-specific probe 
at different developmental stages: whole embryos (E12-E16; A-C), isolated brains (D-F) of newborns 
(NB; D) and three months old mice (3 mo; E, F). Expression can be observed in the posterior 
mesencephalon (A-F) and the dorsal thalamus (A-D; white arrows B-D) (Hesse et al., 2011). 
 
Tcfap2d shows a spatially restricted expression pattern with a predominant 
expression in the fore- and midbrain. The first detection of Tcfap2d occurs on E9.5 in 
the central nervous system and the myocardium (Zhao et al., 2003). In situ 
hybridization on sagittal sections of mouse embryos and isolated brains of newborns 
and 3 months old mice, respectively, localized Tcfap2d to the mesencephalic tectum 
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and the dorsal diencephalon at E12.5 and E14.5 (Fig. 2). During development, 
Tcfap2d exhibits a dynamic expression in that it shifts towards the posterior midbrain. 
This shift in expression is completed at the newborn stage. The dorsal aspect of the 
midbrain is comprised by the anterior colliculi superior and the posterior colliculi 
inferior. In the adult brain, Tcfap2d can be predominantly detected in the posterior 
structure, the colliculi inferior. Tcfap2d is also weakly expressed in the dorsal 
thalamus and the forebrain. This expression persists during embryogenesis and 
adulthood (Fig. 2) (Hesse et al., 2011). In contrast to the other three Tcfap2 genes 
which are all expressed in neural crest cells in the neural fold and head 
mesenchyme, Tcfap2d expression cannot be detected in these tissues. From E13.5 
to E16.5, Tcfap2d signals also persist in the inner nuclear layer of the retina (Zhao et 
al., 2003). In summary, Tcfap2d shows the most restricted and divergent expression 
pattern of Tcfap2 genes; it is not expressed in neural crest cells but is present in the 
developing heart and retina. 
 
1.1.2.5. Ap-2ε 
The fifth and most recent identified member of the Ap-2 family is AP-2ε which 
consists of the typical modular structure with its highly conserved C-terminal DNA 
binding and dimerization domain as well as conserved proline and critical amino acid 
residues in the activation domain (Feng and Williams, 2003; Wang et al., 2004). 
During embryogenesis, Tcfap2e expression can be observed from E7.5 throughout 
all later embryonic stages until birth. It is restricted to neural tissues such as the 
midbrain, hindbrain and olfactory bulb. Within the olfactory bulb, Tcfap2e expression 
becomes refined to the projection neurons and the mitral and tufted cellls. In line with 
the expression pattern, Feng and collegues reported a defective olfactory bulb 
architecture in Tcfap2e null mice. The mitral cell layer was disorganized and the 
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adjacent internal plexiform layer was absent. Despite these findings, Ap-2ε-deficient 
mice could discriminate a variety of odors and were viable and fertile (Feng et al., 
2009).  The data imply that Ap-2ε is required for the establishment of appropriate 
neuronal lamination in the olfactory bulb. 
 
1.1.3. Regulation of Ap-2 proteins 
Early analysis of the human TCFAP2 genomic locus revealed that typical sequence 
motifs for basal transcription factors such as TATA, CCAAT or SP-1 boxes are 
absent in the TCFAP2 promoter (Bauer et al, 1994). Yet, an initiator element and an 
octamer binding site close to the transcriptional start site were reported to be 
indespensable for basal promoter activity (Creaser et al, 1996). Interestingly, AP-2 
consensus binding sequences were identified that confer positive autoregulation. 
Transfection with an AP-2α expression plasmid increased promoter activity of a 
construct containing a partial TCFAP2 fragment including the AP-2 consensus site 
(position -336) (Bauer et al., 1994). Extended TCFAP2A promoter studies revealed 
that the transcription factor BTEB-1 represents an even stronger activator of the 
TCFAP2 promoter than AP-2 itself. Furthermore, the zinc finger protein AP-2rep was 
isolated as a negative regulator conferring strong transcriptional repression of the 
TCFAP2A gene (Imhof et al., 1999). 
Besides these genomic elements that mediate regulation of TCFAP2 transcripts, AP-
2 proteins are mainly influenced by second messengers, posttranslational 
modifications, and protein interactions. Park and Kim could demonstrate that an AP-2 
binding site is required for cAMP activation in the insulin induction of acetyl-CoA 
carboxylase (ACC) gene expression. They could further show that cAMP-dependent 
protein kinase can phosphorylate AP-2α in vitro and in vivo without affecting its 
binding activity (Park and Kim, 1993). A few years later, Garcia et al. reported that 
  Introduction 
  13 
also the APOE (apolipoprotein E) promoter stimulation by cAMP is mediated by AP-
2α.  Protein kinase A phosphorylation of AP-2α at Ser239 did not affect DNA binding 
but enhanced the activatory properties of AP-2α (Garcia et al., 1999). Transcriptional 
activation mediated by AP-2 can also be induced by another signal transduction 
pathway, the phorbol-ester and diacylglycerol-activated protein kinase C (Imagawa et 
al., 1987). Besides the stimulation by forskolin via the cAMP pathway, the stimulation 
by the phorbol ester tumor promoter 12-O-tetradecanoyl-phorbol-3-acetate (TPA) 
also activated a reporter containing a pentameric repeat of an AP-2 binding site 
derived from the SV40 enhancer. These data implicate that cAMP modulates AP-2 
activity by PKA-induced phosphorylation and furthermore that phorbol esters can 
activate AP-2 transactivation involving protein kinase C. 
Human AP-2α transcriptional acitvation was shown to be dually regulated by 
poly(ADP-ribose) polymerase 1 (PARP-1). Interaction with the 
automodification/BRCT (breast cancer suscepitibility gene 1 C-terminal) region of 
PARP-1 increased AP-2 activity. In contrast, the C-terminal catalytic domain of 
PARP-1 strongly interacted with and poly(ADP-ribosyl)ated AP-2α thereby negatively 
affecting AP-2α transcription (Li et al., 2004). 
The HER-2/neu proto-oncogene is overexpressed in approximately one fourth of 
mammary carcinomas (King et al., 1985; King et al., 1989). AP-2 proteins participate 
in HER-2/neu mediated mammary carcinogenesis in that they bind to the HER-2/neu 
promoter and efficiently activate transcription (Bosher et al., 1996; Vernimmen et al., 
2003). HER-2 positive breast cancer cell lines concurrently overexpress AP-2α or 
AP-2γ. This strict correlation suggests that the deregulation of AP-2 proteins is the 
preceding pathological event. Li et al. could show that the increased abundance of 
AP-2 in HER-2/neu mammary carcinomas is due to high stability of the protein. The 
high stability results from reduced ubiquitination of AP-2 in HER2 positive tumor 
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tissues compared to HER2 negative tissues (Li et al., 2006). These data indicate that 
defective ubiquitin-dependent proteasomal degradation pathways may be a major 
cause of increased AP-2 and HER-2/neu levels in breast cancer.  
Other than defective ubiquitination, sumoylation also increases protein stability 
representing another possible reason for increased AP-2 half-lives in tumors (Muller 
et al., 2001). Using a two-hybrid screen, the SUMO-conjugating enzyme UBC9 was 
identified to interact with the C-terminus of AP-2. Furthermore, AP-2 is sumoylated in 
vivo at Lys10 leading to reduced transactivatory potential (Eloranta and Hurst, 2002). 
Interestingly, this site of sumoylation is not conserved in the divergent transactivation 
domain of AP-2δ whereas the proposed region of interaction with UBC9 is 
conserved. 
Another mechanism of regulating AP-2α was proposed by Nyormoi and collegues in 
2001. They demonstrated that the apoptosis-inducer TNF-α downregulated the 
expression of AP-2α and AP-2γ in breast cancer cells (Nyormoi et al., 2001). 
Moreover, recombinant caspase studies suggested that AP-2α is cleaved by caspase 
6. Cleavage of AP-2α in vivo led to AP-2α degradation and loss of DNA binding 
activity indicating that AP-2α is a critical component during TNF-α induced apoptosis.  
Protein interactions can also negatively regulate AP-2 activation by displacing AP-2 
proteins from their binding sites. For example, Nuclear Factor 1 (NF-1) and AP-2 bind 
mutually exclusive to the same region of the hGH promoter as AP-2 binding only 
occurs if NF-1 binding is prevented (Courtois et al., 1990). Mercurio and Karin 
described another case where AP-2 was replaced by another DNA binding factor. 
AP-2 and AP-3 competed for binding to the SV40 core sequence in which the binding 
sites for both proteins are overlapping (Mercurio and Karin, 1989). In a very recent 
report, the interaction between AP-2 and potassium channel tetramerization domain-
containing 1 (KCTD1) at the N-termini of both proteins was described. This 
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interaction significantly repressed AP-2α-mediated transactivation (Ding et al., 2009). 
Taken together, these data define different means to posttranslationally regulate AP-
2 activity. 
 
1.1.4. Initiation of AP-2-mediated transcription via interaction partners 
AP-2 proteins positively or negatively regulate transcription of target genes by 
cooperation with other transcription factors or coactivators which augment building a 
link to the basal transcriptional machinery.  
Two members of the CITED family, CITED2 and CITED4, have been shown to 
physically interact with and coactivate AP-2α, AP-2β, and AP-2γ by linking them to 
p300 and CBP (Bamforth et al., 2001; Braganca et al., 2003; Braganca et al., 2002). 
p300 and CBP exert an intrinsic histone acetyltransferase activity. The transfer of 
acetyl groups to histone tails results in the relaxation of tightly packed 
heterochromatin and renders DNA more accessible to transcription factors. Despite 
the presence of conserved residues at the N- and C-termini of the two CITED 
proteins, CITED2 mediates binding and transactivation of AP-2 proteins through its 
C-terminus whereas residues 2-20 of the N-terminus as well as the C-terminus are 
essential for co-activation by CITED4. Moreover, Cited2 and Ap-2 occupied the 
murine Pitx2c promoter in vivo and cooperatively transactivated this promoter in 
transient transfection assays (Bamforth et al., 2004).  
AP-2α has been implicated in the regulation of the hamster histone H3.2 gene 
together with the transcription factor YY1. It was shown to interact with the N-
terminus of YY1 through its DNA binding and dimerization domain. Although AP-2α 
and YY1 can independently bind to AP-2 and YY1 binding sites in the hamster H3.2 
promoter, they were both found in a complex that binds to the AP-2 binding sites (Wu 
and Lee, 2001) indicating a modulation of AP-2 activity by physical interaction with 
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YY1. YY1 and AP-2 binding sites were also found in the galactocerebrosidase 
(GALC) gene and gave rise to the assumption that AP-2 and YY1 are involved the 
transcriptional suppression of the GALC gene (Beier and Gorogh, 2005). 
 
1.1.5. Interaction with tumor suppressors 
The tumor suppressor RB encoded by the retinoblastoma gene has been shown to 
restrict cell proliferation, promote cell differentiation, and promote apoptosis by acting 
as either a positive or negative regulator of transcription (for review see (Harbour and 
Dean, 2000; Lipinski and Jacks, 1999; Wang, 1997)). In the context of epithelial 
differentiation, it activates the E-cadherin gene by directly binding to AP-2 in vivo and 
acting synergistically with it (Batsche et al., 1998b). Similarly, the positive regulation 
of the BCL-2 gene by RB also requires the interaction with AP-2 in the same cells 
(Decary et al., 2002). Both proteins bind to the same sequences within the E-
cadherin and BCL-2 promoters suggesting that a complex containing these two 
proteins cooperatively activates gene transcription in epithelial cells. Interestingly, E-
cadherin and BCL-2 promoters were found to be highly acetylated when bound by 
RB and AP-2 linking activation again to the association of AP-2 with the coactivator 
p300 that exhibits acetyltransferase activity (Decary et al., 2002). Activation of BCL-2 
by AP-2 is in line with the observation of apoptotic cell death with downregulation of 
bcl-2 in the absence of Ap-2β in knockout mice (Moser et al., 1997). In contrast, 
repression of the bcl-2 gene was reported by Wajapeyee and collegues during Ap-
2α-elicited apoptosis. Adenoviral- or chemotherapy-induced overexpressed Ap-2α 
binds to a more proximal binding site in the bcl-2 promoter and reduced Bcl-2 gene 
transcription via a bax/cytochrome c/Apaf1/caspase-9-dependent mitochondrial 
pathway (Wajapeyee et al., 2006). 
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A direct protein-protein interaction with AP-2α and AP-2γ was also demonstrated for 
another tumor suppressor protein, p53. Interaction of AP-2 with p53 augmented the 
transactivation of a p53-responsive promoter. Moreover, AP-2 and p53 bind in vivo to 
the p21Waf1/CIP1 promoter at a p53 binding site and p53-mediated induction of p21 
mRNA is supported by the association of AP-2 to p53. AP-2 was able to induce G1 
and G2 cell cycle arrest only in the presence of p53 (McPherson et al., 2002). These 
results may explain the tumor suppressor function ascribed to AP-2 in breast cancer, 
colon cancer, and malignant melanoma (Gee et al., 1999; Karjalainen et al., 1998; 
Ropponen et al., 2001).  
 
1.1.6. Ash2l represents an interaction partner for Ap-2δ 
Up to date, only one interaction partner has been described for Ap-2δ. Using a yeast 
two-hybrid screen, the trithorax superfamily member Ash2l was identified to bind 
exclusively to the TAD of Ap-2δ and synergistically activate Ap-2δ-mediated gene 
expression in a dose-dependent manner. Ap-2δ was shown to associate with 
endogenous Ash2l and Alr, a member of the MLL family of histone lysine 
methyltransferases. This complex is able to methylate lysine 4 of histone 3 (H3K4). 
Intriguingly, Ap-2δ is essential for the recruitment of Ash2l and Alr to the Hoxc8 locus 
and formation of this complex leads to H3K4 trimethylation and subsequent gene 
activation (Tan et al., 2008). Using microarray analysis, gene expression profiles 
were produced from Ap-2δ and Ash2l-deficient Neuro2a cells. By this approach, 
Fgfr3 was identified as a direct transcriptional target of the Ap-2δ-Ash2l complex. 
Similar to the Hoxc8 locus, Ap-2δ is also responsible for the recruitment of the Ash2l-
containing complex to the Fgfr3 promoter resulting in H3K4 trimethylation (Tan et al., 
2009). The data provide for the first time evidence that Ap-2δ has a functional role in 
recruiting histone methyltransferases to specifc gene loci in a spatiotemporal manner. 
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Owing to the highly restricted expression pattern of Ap-2δ and its sequence-specific 
DNA binding properties, these findings present a mechanism how MLL family 
members achieve specificity despite their global expression patterns (Tan et al., 
2008). 
 
1.2. The family of NFAT transcription factors 
The nuclear factor of activated T cells (NFAT) family of transcription factors plays 
pivotal roles in many vertebrate developmental events as diverse as immune 
responses, axonal outgrowth, cardiac and lung morphogenesis and neural crest 
diversification (Crabtree and Olson, 2002; Graef et al., 2001; Macian, 2005).  
Five family members have been currently idenitified and are named NFATc1/2/c,  
NFATc2/1/p, NFATc3/4/x, NFATc4/3, and NFAT5/TonEBP (Graef et al., 2001; 
Macian, 2005; Rao et al., 1997). Structural analysis of these proteins revealed a 
highly conserved DNA binding domain that shares a homology of approximately 70% 
among NFATc proteins (Serfling et al., 2004). This domain is also called “Rel 
homology region” (RHR) due to its structural similarity to the DNA binding domain of 
Rel/Nf-κb family transcription factors. 
 
 
Figure 3: Structure of NFAT proteins. NFAT proteins are composed of a highly conserved DNA 
binding region also termed Rel homology region (RHR) and a less conserved Nfat homology region 
(NHR) that contains a N-terminal transactivation domain (TAD) and the regulatoty region with 
calcineurin docking site and SRR and SP motifs. SRR = serine rich region, SP = serine proline 
phosphorylation motif, NLS = nuclear localization signal (Mancini and Toker, 2009) 
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NFATc1-4 furthermore share a strong TAD located at the N-terminus followed by the 
NFAT homology region which contains regulatory elements. The latter comprises 
elements relevant for proper NFAT function including several serine rich regions 
(SRR), serine-proline phosphorylation motifs, a calcineurin docking site, and a 
nuclear localization signal (NLS) (Fig. 3). 
 
1.2.1. Calcium-calcineurin-NFAT signaling pathway 
NFAT activation is elicited by a rise in intracellular calcium levels initiated by cell 
surface receptors that stimulate activation of phospholipase Cγ (PLCγ). Activated 
PLC enzymes initiate release of calcium from the endoplasmic reticulum. In 
response, calcium-release activated calcium channels (CRAC) are opened which 
confer a sustained calcium signal. Calcium is bound by calmodulin which activates 
the serine/threonine phosphatase calcineurin (Clipstone and Crabtree, 1992; Hogan 
et al., 2003; Jain et al., 1993). 
In resting cells, NFAT is located in a highly phosphorylated state in the cytoplasm 
(Fig. 4). It only shows a weak affinity for DNA binding (Viola et al., 2005). Upon rise in 
intracellular calcium levels and subsequent calcineurin activation, calcineurin binds to 
NFAT within the regulatory domain and dephosphorylates up to 18 serine residues. 
This evokes a conformational change which masks a nuclear export signal (NES) 
and exposes the NLS promoting translocalization to the nucleus and an increase in 
DNA binding affinity (Beals et al., 1997; Okamura et al., 2004). Calcineurin also 
maintains NFAT in a dephosphorylated state in the nucleus (Zhu and McKeon, 1999). 
Nuclear localization is temporally restricted and counteracted by several kinases 
such as glycogen synthase kinase 3 (GSK-3) (Neal and Clipstone, 2001), casein 
kinase 1 (CK1) (Okamura et al., 2004), and tyrosine-phosphorylation regulated 
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kinases (DYRK) (Gwack et al., 2006) that sequentially rephosphorylate the serine 
residues.  
 
 
Figure 4: Calcineurin-NFAT-signaling. Increased intracellular calcium activates calcineurin which 
dephosphorylates Nfat promoting nuclear entry. In the nucleus, Nfat binds to DNA together with other 
transcription factors and coactivators to initiate transcription of target genes. This function is 
counteracted by Nfat kinases such as GSK-3, CK1 and DYRK that rephosphorylate Nfat resulting in 
nuclear exit. Calcineurin activity can be inhibited by the immunosuppressive drugs CsA and FK506. 
(Modified from Cooling et al, 2009) 
 
Thus, NFAT loses its DNA binding affinity and is transported out of the nucleus into 
the cytoplasm. GSK-3 and DYRK-1 act as export kinases, whereas CK1 can function 
as both export and maintenance kinase. DYRK-2 phosphorylates NFAT in the 
cytoplasm and acts as a maintenance kinase. In summary, NFAT activation relies on 
the balance between calcineurin-mediated dephosphorylation and NFAT-kinase-
regulated rephosphorylation.  
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Calcineurin-NFAT signalling represents a target for immunosuppressive drugs such 
as cyclosporin A (CsA) and FK506. These drugs block nuclear localization of NFAT 
by inhibiting calcineurin phosphatase activity. CsA and FK506 bind at subnanomolar 
affinity to the intracellular proteins cyclophilin and FKBP, respectively. This 
drug/protein composite surface then binds to calcineurin, thereby inhibiting substrate 
access (Liu et al., 1991). 
NFAT5 is the most divergent family member. It has a distinct domain structure as it 
does not contain a calcineurin docking site and thus is calcium and calcineurin-
insensitive (Lopez-Rodriguez et al., 1999). Its activation is regulated via osmotic 
pressure (Lee and Park, 2006). 
In addition to phosphorylation, NFAT acitivity is also modulated by other 
posttranscriptional modifications. Sumoylation of NFAT proteins represents another 
means of NFAT regulation as it results in nuclear retention of the transcription factor 
(Nayak et al., 2009; Terui et al., 2004). In breast cancer cells, NFAT1 has also been 
shown to be ubiqitinated by the E3 ubiqitinin ligase murine double minute 2 (MDM2) 
that targets the transcription factor for degradation (Yoeli-Lerner et al., 2005). These 
data demonstrate the complexity of the mechanisms required for NFAT activation. 
 
1.2.2. Knockout animal studies of Nfat  
Targeted disruption of Nfat genes has defined roles in development of the 
cardiovascular, musculoskeleton, and nervous system with complicated 
immunological phenotypes. The resulting phenotypes suggest redundancy but also 
isoform-specific differences among Nfatc1-4 (Table 1). 
Nfatc1 null mice are embryonically lethal with defects in cardiac valve formation (de 
la Pompa et al., 1998; Ranger et al., 1998). Nfatc2-deficient mice suffer from 
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hyperproliferation of splenic B and T cells and display dysregulation of 
chondrogenesis (Ranger et al., 1998; Xanthoudakis et al., 1996).  
 
Table 1: Phenotypes of Nfat knockout mice (modified from Crabtree and Olson, 2002; Kiani et al., 
2000) 
Nfat protein Phenotype of knockout mice 
Nfatc1/2/c Embryonic lethality (heart valve defect) 
Lymphocytes produce less IL-4 
Nfatc2/1/p Immune hyperactivation and allergic responses, suppression 
of chondrogenesis 
Nfatc3/4/x Defect in positive selection of thymocytes, hyperproliferation 
of lymphocytes 
Nfatc4/3 Viable and fertile, no apparent defects 
c1 + c2 Failure of T cell and immune response gene activation 
c2 + c3 Spontaneous Th1 differentiation, excessive allergic response 
c3 + c4 Lethal vascular patterning defects 
Nfat5/TonEBP Knockouts not reported yet, Nfat5 is not implicated in 
regulation of conventional Nfat target genes 
 
Nfatc3 knockout mice exhibit defects in myogenesis as well as reduced thymocyte 
numbers (Amasaki et al., 2002; Oukka et al., 1998). Mice with a targeted disruption of 
Nfatc4 appear to be developmentally normal (Graef et al., 2001). More pronounced 
phenotypes are evident when more than one Nfat isoform is deleted. Double mutant 
mice for Nfatc1 and Nfatc2 show an impaired activation of cytokine genes because 
no IL-2, IL-4 and TNF-a were produced (Peng et al., 2001). Nfatc2/Nfatc3 knockout 
mice display spontaneous differentiation into Th2 cells as well as severe allergic 
responses with extremely high levels of IgE (Ranger et al., 1998). Nfatc3/Nfatc4 null 
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mice have profound defects in angiogenesis characterized by vessel instability and 
disorganization which result in embryonic lethality at approximately E11.5 (Graef et 
al., 2001). 
 
1.2.3. Regulation of target genes via interaction with other transcription factors 
NFAT family members have been shown to regulate transcription through the 
cooperative binding to DNA sites in concert with other transcription factors. 
Interaction of transcription factors stimulated via distinct signaling pathways 
constitutes an important mechanism to integrate these signals and elicit cellular 
response. NFAT proteins do so by cooperation with AP-1 transcription factors. 
Whereas NFAT proteins are regulated by calcium and calcineurin, AP-1 proteins are 
regulated by other pathways including MAPkinase/PKC and Ras. NFAT and AP-1 
proteins cooperate in promoter/enhancer regions of several genes in immune cells 
(reviewed in Rao et al., 1997). Most of the known binding sites in these genes are 
composite Nfat/Ap-1 DNA elements which are composed of a Nfat binding sequence 
(GGAAA) adjacent to an often weak Ap-1 site. The resulting ternary protein complex 
consists of one Nfat monomer and one homo- or heterodimer produced by the AP-1 
proteins fos and jun (Macian, 2005). 
Several studies have also shown the cooperate activation of gene transcription by 
Nfat and Sp-1 proteins. These two transcription factors are responsible for FasL gene 
activation in IL-2 treated T cells. The critical region for this regulation contains an Sp-
1 as well as an Nfat binding site which are partially overlapping. Mutation of either 
binding site reduced FasL promoter activity (Xiao et al., 1999). Nfat and Sp-1 also 
physically interact in mammalian cells in a calcineurin-dependent manner as 
interaction upon treatment with CsA could no longer be observed (Santini et al., 
2001). Because Sp-1 factors are not sensitive to calcium or calcineurin treatment, 
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calcineurin controls Nfat proteins that bind to Sp-1, thereby enhancing Sp-1 
transactivating abilities at the p21WAF1/CIP1 promoter in keratinocytes leading to 
differentiation (Santini et al., 2001). 
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1.3. Aim of this study 
The murine cDNA encoding Ap-2δ was isolated in 2001 by Zhao and collegues 
(Zhao et al., 2001). In contrast to other Ap-2 proteins, Ap-2δ lacks a conserved PY 
motif and several other critical residues in the transactivation domain which are 
thought to be important for the activatory potential of Ap-2 proteins. Ap-2δ is mainly 
expressed in the midbrain, the myocardium and the retina. During development, Ap-
2δ expression shows a dynamic shift from the mesencephalic tectum and the dorsal 
diencephalon to the posterior part of the midbrain, the colliculus inferior. 
The genetic disruption of the Tcfap2d gene revealed the absence of the colliculus 
inferior in Ap-2δ-deficient mice. Loss of Ap-2δ results in the degradation of this 
structure due to massive apoptosis indicating an essential role for Ap-2δ in the 
maintenance and further maturation of the posterior midbrain.  
1.  To understand Ap-2δ-dependent control of the posterior midbrain, one aim of 
the present study was to identify Ap-2δ specific target genes in vivo that are 
involved in the formation of this brain structure. Microarray analyses revealed 
genes that were differentially regulated in the posterior midbrain of Ap-2δ-
deficient mice compared to wildtype controls. With the help of different 
biochemical and cellular assays, the contribution of Ap-2δ to the activation of 
these altered genes was examined. 
2.  Although Ap-2δ lacks critical motifs in the transactivation domain that are 
conserved in other Ap-2 proteins, Ap-2δ does not exhibit a reduced 
transactivation potential compared to other isoforms. The divergent 
transactivation domain furthermore implicates an involvement of other 
coactivators and interaction partners than those known for other Ap-2 family 
members. A yeast-two hybrid screen identified the transcription factors Nfatc2 
and FoxG1 as putative interaction partners of Ap-2δ. In the present work, 
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these interactions were characterized by in vitro and in vivo assays. In 
addition, the synergistical activation of target genes by both transcription 
factors was analyzed. 
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2. Materials and Methods 
2.1. Material 
2.1.1. Chemicals 
 
Chemicals Manufacturer Location 
2-Propanol Merck Darmstadt 
Acetic acid Merck Darmstadt 
Acrylamide (Rotiphorese Gel 30) Carl Roth GmbH Karlsruhe 
Agar Merck Darmstadt 
Agarose Sigma Aldrich  St. Louis, USA 
Ammonium peroxisulfate (APS) Carl Roth GmbH  Karlsruhe 
Ampicillin Carl Roth GmbH  Karlsruhe 
β-mercaptoethanol Sigma Aldrich St. Louis, USA 
Bovine serum albumin (BSA) Sigma Aldrich  St. Louis, USA 
Calcium chloride Merck Darmstadt 
Chloroform Merck Darmstadt 
Complete Mini Roche Diagnostics  Mannheim 
Dimethyl sulfoxide (DMSO) Sigma Aldrich  St. Louis, USA 
dNTPs Invitrogen  Karlsruhe 
Dulbecco´s MEM Invitrogen  Karlsruhe 
Dynabeads® Invitrogen  Karlsruhe 
ECL reagent Perbio  Bonn 
Ethanol Merck  Darmstadt 
Ethidium bromide Sigma Aldrich  St. Louis, USA 
Ethylenediaminetetraacetic acid Merck Darmstadt 
Exacta Cruz BTM Santa Cruz Heidelberg 
Fetal calf serum Invitrogen  Karlsruhe 
Glycerol Sigma Aldrich  St. Louis, USA 
Glycine Sigma Aldrich  St. Louis, USA 
HEPES Sigma Aldrich  St. Louis, USA 
Hoechst 33342 Invitrogen Karlsruhe 
Horse radish peroxidase (HRP) Sigma Aldrich  St. Louis, USA 
Isopropanol Sigma Aldrich  St. Louis, USA 
IPTG Merck  Darmstadt 
LipofectamineTM Invitrogen Karlsruhe 
Luciferin Roche Pensheim 
Methanol Merck  Darmstadt 
Non-fat dry milk Merck Darmstadt 
NP-40 Calbiochem  Darmstadt 
Penicillin/Streptomycin Invitrogen  Karlsruhe 
Paraformaldehyde Merck Darmstadt 
Potassium chloride Merck Darmstadt 
RNase-OutTM Invitrogen  Karlsruhe 
Roti®-load 4x concentrate Carl Roth  Karlsruhe 
Salmon sperm DNA Invitrogen  Karlsruhe 
Sodium acetate Merck Darmstadt 
Sodium chloride Merck  Darmstadt 
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Sodium dodecyl sulfate (SDS) Merck  Darmstadt 
Skim milk powder Sigma Aldrich  St. Louis, USA 
TEMED Bio Rad  Hercules, USA 
Trishydroxymethylaminomethane 
(Tris) 
Merck  Darmstadt 
Triton-X100 Sigma Aldrich  St. Louis, USA 
TRIzol® Reagent Invitrogen  Karlsruhe 
Tween-20 Sigma Aldrich  St. Louis, USA 
 
2.1.2. Apparatus 
 
Apparatus Manufacturer  Location 
Abiprism 7900HT  Applied Biosystems  Foster City, USA 
Bacteria shaker Innova 
4000 
New Brunswick Scientific  Nürtingen 
Centrifuges 5415D Eppendorf  Hamburg 
Centrifuges 5417R Eppendorf  Hamburg 
ELISA Reader ELx800  BioTek Instruments  Winooski, USA 
Hoefer Dual Gel Caster Amersham Bioscience  Freiburg 
Luminometer Centro Berthold Technologies Bad Wildbad 
Magnetic stirrer Ika-Combimag RCT, IKA-
Werke GmbH  
Staufen 
Membrane pump M72C, Vacubrand GmbH 
& Co  
Wertheim 
Microscope Axioscop50 Zeiss  
Leica  
Oberkochen                    
Wetzlar 
Millipore-Pelicon Filtration 
device  
Millipore Molsheim, France 
Nano Drop  Peqlab Biotechnologie  Erlangen 
pH-meter MP 220, Mettler Toledo  Greifensee, Switzerland 
Pipettes Gilson Pipetman 
Eppendorf 
Langenfeld  
Hamburg 
Power supplies E143 Consort  Turnhout, Belgien 
Shakers Series 25 New Brunswick 
Scientific CO., Inc.   
Multitron, Infors AG  
Edison, USA  
 
Bottmingen, Switzerland 
Sterile bench Biohazard, Gelaire 
Heraeus-Christ 
Mailand, Italy  
Hanau 
Thermocycler Analytik Jena Jena 
Thermomixer compact Eppendorf  Hamburg 
TransBlot Semi-Dry 
Transfer  
Bio- Rad  Hercules, USA 
UV-imaging system Intas UV system  Göttingen 
UV-transilluminator Biometra  Göttingen 
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2.1.3. Consumables 
 
Consumables Manufacturer Location 
1.5 ml tubes Sarstedt Nümbrecht 
2 ml tubes Sarstedt Nümbrecht 
200 µl PCR tubes Axygen Union City, USA 
12-well cell culture plates Costar  Lowell, USA 
6-well cell culture plates Costar Lowell, USA 
10 cm cell culture dishes Costar Lowell, USA 
75T cell culture plates Costar  Lowell, USA 
96-well LB luminometer 
plates  
Nunc  Wiesbaden 
Autoradiography film Kodak  New Haven, USA 
Cryo Tubes™ Nunc  Wiesbaden 
Falcon 2052 Costar  Lowell, USA 
Petri dishes Costar  Lowell, USA 
PVDF transfer membrane Roth Karlsruhe 
 
2.1.4. Kits 
 
Kits Manufacturer Location 
NucleoBond Xtra Maxi 
Plus 
Macherey-Nagel  Düren 
Zymoclean Gel DNA 
recovery kit 
Zymo Research  Freiburg 
High Pure PCR 
purification kit 
Roche  Penzberg 
SYBR® Green Taq PCR 
MixTM 
Invitrogen Karlsruhe 
TOPO TA cloning® Invitrogen  Karlsruhe 
Exacta Cruz 
Immunoprecipitation kit 
Santa Cruz Heidelberg 
 
  
2.1.5. Enzymes and markers 
 
Enzyme Manufacturer Location 
DNA 100 bp laddder Invitrogen Karlsruhe 
DNA 1 kb ladder Invitrogen Karlsruhe 
Prestained SDS-PAGE 
standard 
Invitrogen Karlsruhe 
DNase I NEB Schwalbach 
RNase NEB Schwalbach 
Platinum Taq High Fidelity 
Polymerase 
Invitrogen Karlsruhe 
Klenow Invitrogen Karlsruhe 
Proteinase K Merck Darmstadt 
Restriction endonucleases NEB Schwalbach 
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RNAseOUT Invitrogen Karlsruhe 
Shrimp Alkaline Phosphatase New England BioLabs Frankfurt 
SuperScript III Reverse 
Transcriptase 
Invitrogen Karlsbad 
T4 DNA ligase Invitrogen Karlsruhe 
Trypsin EDTA (0.25% / 0.02%) Invitrogen Karlsruhe 
 
2.1.6. Antibodies 
 
Antibodies Manufacturer Location 
Rabbit polyclonal Ap-2δ 
antiserum 
PD Dr. Markus Moser Martinsried 
Mouse monoclonal Nfatc2 
antibody 
abcam Cambridge, UK 
Mouse monoclonal HA.11 
antibody (hemagglutinin 
tag) 
Covance Emeryville, USA 
Rabbit polyclonal histone 
H3 antibody 
abcam Cambridge, UK 
Mouse-monoclonal ß-
Actin antibody (AC15) 
Sigma Aldrich  St. Louis, USA 
Mouse IgG antibody Diagenode Liège, Belgium 
Rabbit IgG antibody Diagenode Liège, Belgium 
Goat polyclonal antibody 
anti-rabbit HRP conjugate 
Dako  Glostrup, Denmark 
Goat polyclonal antibody 
anti-mouse HRP 
conjugate 
Dako  Glostrup, Denmark 
Alexa Fluor 594 goat anti-
mouse IgG 
Invitrogen Karlsruhe 
Alexa Fluor 488 goat anti-
rabbit IgG 
invitrogen Karlsruhe 
 
2.1.7. Vectors 
 
Vector Insert Source 
pCMX-PL1  Umesono et al., 1991 
pCMX-mAp-2δ mAp-2δ cDNA PD Dr. M. Moser, 
Martinsried 
pCMX-HA-mAp-2δ mAp-2δ cDNA, N-terminal 
HA-tag 
this work 
pCMX-Flag-mAp-2δ mAp-2δ cDNA, N-terminal 
Flag-tag 
this work 
pCMX-HA-mNfatc2 mNfatc2 cDNA, N-terminal 
HA-tag 
this work 
pCMX-HA-mFoxG1 mFoxG1 cDNA, N-terminal 
HA-tag 
this work 
pGl3-basic luciferase reporter Promega, Mannheim 
pGl3-Bhlhb4 -300bp 300 bp mBhlhb4 promoter this work 
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fragment 
pGl3-Bhlhb4 -1.8kb 1.8 kb mBhlhb4 promoter 
fragment 
this work 
pGl3-Pou4f3-2.6kb 2.6 kb mPou4f3 promoter 
fragment 
this work 
pSG5  Stratagene, Amsterdam 
pSG5-mAp-2δ mAp-2δ cDNA this work 
pSG5-HA-mAp-2δ mAp-2δ cDNA, N-terminal 
HA-tag 
this work 
pGEX-3x  Amersham, GE 
Healthcare, München 
pGEX-3x-mAp-2δ TAD mAp-2δ TAD PD Dr. M. Moser, 
Martinsried 
pGEX-3x-GST  PD Dr. Jutta Kirfel, Bonn 
pCR®II-TOPO  Invitrogen, Karlsruhe 
 
 
2.1.8. Primers and oligonucleotides 
 
qRT-PCR primers 5’-3’ 
Tcfap2d F: TCATGTCAACTACCTTTCCCG 
R: GAACTCGTAATGGAAGGACTGG 
Pou4f3 F: AACCCAAATTCTCCAGCCTAC 
R: GCGAGGTAGAAGTGCAGG 
Bdnf F: GCCCAACGAAGAAAACCATAAG 
R: AGGAGGCTCCAAAGGCACTT 
Calbindin2 F: GATGGGAAAATTGAGATGGCG 
R: AGTATGGTCTGGGTGTACTCC 
Lhx3 F: ACTACGAAACAGCCAAGCAG 
R: CAGTCTCTTTTCCTTAGCCCG 
Nfatc2 F: ACGGGAGTGACCGTCAAA 
R: GGAGGGAGGTCCTGAAAACT 
Atm F: GGACTCCAGCTTTAAAGATAAAGAGA 
R: TGCAGGGTTTTCTAAGCAAGT 
c-Fos F: GGGGCAAAGTAGAGCAGCTA 
R: AGCTCCCTCCTCCGATTC 
Egr3 F: CAATCTGTACCCCGAGGAGA 
R: CCGATGTCCATCACATTCTCT 
Itpr1 F: ACCGGAAGCTGAGAACTCC 
R: TGGTCTTCCAGTTGCCTCA 
Mtss1 F: AGCTGCAGAAGAAGGCAAAA 
R: TTTCCTCCAACAGGAGGTATTT 
ChIP primers  5’-3’ 
Bhlhb4-300 bp F: AGAAATGGCAGTTGAGGGG 
R: AATCAGAGGGGACCTGCTG 
Bhlhb4-1.8 kb F: TCTCTTCCTAGCCTCCCACA 
R: GCTGTTCAGGGGAGTCTGTC 
Pou4f3-2.6 kb F: TGACCATTGCTAGTGGACCTT 
R: CCAATGCGGTTCA ACAGAC 
Atm bs1 F: TAGCAGCTGGTTCTGTACGC 
R: GGTTGTGGCCAGAGAGGAC    
Atm bs2 F: TTCTTGCTCTCATCCCTTCC 
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R: TAGCCGAGGAAGGACTGGTT 
Egr3 bs1 F: CCCAATTGCCTGGCTCTC 
R: GCGGTGTGAGCCTAGCTG 
Egr3 bs2 F: AAACTGAGGGGAGGGAAGAG 
R: GGGAACTTGCATCTCTCAGG 
ITPR1 bs1 F: TAGATGGGAGGCAGGAAGTG 
R: TGTCCATGCTGTCTGGAATC 
ITPR1 bs2 F: TCAGACACAAGTTCGCAACC 
R: GCTTATATAGGCCGGGAAGC   
ITPR1 bs3 F: CTAACCCCTCTCCTGGTCCT 
R: CACCAAAGCCACCAAGAACT   
Mtss1 bs1 F: AAAAATGCCCGGAGAAGACT 
R: GCTGCCCTTTTTCGTTCTCT 
Mtss1 bs2 F: CCGCCTCCTTTTTACTCCTG 
R: CTCTGCACGCCTCTCAGC   
Mtss1 bs3 F: CGGATCTGTTGAGGCAGACT 
R: GGTTTTCTGGTGCTCAGAGG   
Mtss1 bs4 F: AAGCACTCCACCCCAAACC 
R: CGGCTGCTCTGACCTCG    
Oligonucleotides for EMSA 5’-3’ 
Zhao F: GAACTGACCGCCTGAGGCGCGTGTGCA 
R: TGCACACGCGCCTCAGGCGGTCAGTT 
Pou wt F: TTTCTAGGGGCCTGAGGGAAGTAGTGG 
R: CCACTACTTCCCTCAGGCCC 
Pou mt1 F: TTTCTAGGGGCCAGTGGGAAGTAGTGG 
R: CCACTACTTCCCACTGGCCC 
Pou mt2 F: TTTCTAGGGGCCGTTGGGAAGTAGTGG 
R: CCACTACTTCCCAACGGCCC 
Bhlhb4 F: CGCGGAACCTGAGGGCGCTTT 
R: GCCTTGGACTCCCGCGAAA 
 
 
2.1.9. siRNA oligonucleotides 
 
siRNA Manufacturer Location 
All stars negative control 
siRNA 
Qiagen Hilden 
mAp-2δ siRNA Ambion Austin, USA 
Block-iTTM fluorescent 
control siRNA 
Invitrogen Karlsruhe 
 
 
 
 
 
2.1.10 Media, buffers, and solutions 
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2.1.10.1. Cell culture and bacterial growth media 
 
Media, buffers, solutions Composition 
Cell culture medium Dulbecco's Modified Eagle Medium with 4.5 g/L D-
Glucose, 10 % FCS, 2 mM L-Glutamine, 100 U/mL 
penicillin, 100 µg/mL streptomycin 
1x trypsin/EDTA 500 mg/L trypsin, 200 mg/L EDTA in 1x HBS 
LB medium 10 g tryptone 
  5 g yeast extract 
10 g NaCl 
ad 1 L H2O 
LB plates 15 g bacto agar  
10 g tryptone  
  5 g yeast extract 
10 g NaCl 
ad 1 L H2O 
Ampicillin stock solution 100 mg/mL in H2O 
 
 
2.1.10.2. Nucleic acid analysis 
 
Buffer Composition 
Buffer 1 (lysis) 50 mM Tris-HCl pH 8.0 
10 mM EDTA 
Buffer 2 (denaturation) 200 mM NaOH 
1% SDS 
Buffer 3 (neutralization) 3 M KAc pH 5.5 
DNA loading buffer 50% glycerol 
50% H2O 
spatula point bromophenolblue 
spatula point xylenecyanol 
0.5x TAE 
50x TAE 2 M Tris(hydroymethyl)aminomethane 
1 M NaAc 
50 mM EDTA 
10x TBE 890 mM Tris 
890 mM boric acid 
20 mM (Na2)-EDTA 
20x MOPS 800 mM MOPS 
200 mM NaAc 
20 mM EDTA 
2x BES 50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4x2H2O 
pH 6.96 
 
2.1.10.3. Immunoblotting and protein assays 
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Buffer Composition 
RIPA buffer 150 mM NaCl 
0.5 % Na-deoxycholate 
1 % NP-40 
0.1 % SDS 
50 mM Tris pH 7.5 
1 tablet Complete Mini (protease inhibitor, Roche, 
Penzberg)/10 ml buffer 
5x Laemmli Running buffer 25 mM Tris 
250 mM glycine 
0.1 % SDS 
Transfer buffer 48 mM Tris 
39 mM glycine 
1.3 mM SDS 
5% methanol 
PBST 0.01% Tween-20 in PBS 
Co-IP Lysis buffer 20 mM Tris-HCl pH 8 
137 mM NaCl 
10% glycerol 
1% NP-40 
2 mM EDTA 
before use add protease inhibitor 
Coomassie solution 0.1% Coomassie brilliant blue 
50% methanol 
7% acetic acid 
Destain solution 50% methanol 
7% acetic acid 
Luciferase Lysis buffer 125 mM Tris pH 7.8 
10 mM EDTA 
100 mM DTT 
50% glycerol 
5% Triton X-100 
Luciferase Assay buffer 20 mM Tricine 
1.07 mM (MgCO3)4 
2.67 mM MgSo4 
0.1 mM EDTA 
33.3 mM DTT 
0.27 mM Coenzyme A 
0.47 mM Luciferin 
0.53 mM ATP 
Pulldown interaction buffer 20 mM Hepes pH 7.7 
75mM KCl 
0.1 mM EDTA 
25 mM MgCl2 
10 mM DTT 
0.15% NP-40 
EMSA binding buffer 10 mM Tris pH 7.5 
1 mM MgCl2  
50 mM NaCl  
0.5 mM EDTA  
0.5 mM DTT  
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4% glycerol  
0.05 mg/ml poly (dI-dC) 
 
 
2.1.10.4. Chromatin immunoprecipitation 
Buffer Composition 
SDS lysis buffer 50 mM Tris 
10 mM EDTA 
0.1 % SDS 
Dilution buffer 16.7 mM Tris 
167 mM NaCl 
1.2 mM EDTA 
0.01 % SDS 
1.1 % Triton X-100 
TE buffer 10 mM Tris 
1 mM EDTA 
Wash buffer 0.01% Tween 20 in TE buffer 
Elution buffer 20 mM Tris 
5 mM EDTA 
50 mM NaCl 
1% SDS 
 
 
2.1.11. Bacterial strains 
 
Bacteria (E. coli strains) Genotype 
DH5α  F-, φ80lacZ∆M15, ∆(lacZYA-argF)U169, 
recA1, endA1, hsdR17(rk-, mk+), phoA, 
supE44, thi-1, gyrA96, relA1 and tonA 
TOP10  F-, mcrA, ∆(mrr-hsdRMS-mcrBC), 
Φ80lacZ∆M15, ∆lacX74, recA1, 
araD139, ∆(araleu)7697, galU, galK, 
rpsL, (StrR),endA1 and nupG 
BL21  F-, ompT, hsdSB (rB
– mB
–), gal, dcm 
 
 
2.1.12. Cell lines 
 
Cell line Description 
Neuro2a mouse neuroblastoma cell line 
NIH/3T3 mouse embryonic fibroblast cell line 
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2.2. Methods 
2.2.1. Cell Culture 
Neuro2a and NIH/3T3 cells were cultured as an adherent monolayer in Dulbecco's 
Modified Eagle Medium supplemented with 10% fetal calf serum and 1% glutamine 
and penicillin/streptomycin in a humidified atmosphere with 5% CO2 at 37°C. The 
adherent cells were removed from cell culture dishes with a 1x 
trypsin/ethylenediaminetetraacetic acid (EDTA) solution (10% 10x trypsin/EDTA + 
90% PBS) incubated for 3 minutes at 37°C and split 1-2 times per week in a ratio of 
1:5–1:10.  
 
2.2.1.1. Cryo-conservation of cells 
To be able to revert to a constant cell population in case of need, cells were 
conserved at -196°C in liquid nitrogen. Cells were supplied with freezing medium 
(FCS with 10% dimethyl sulfoxide (DMSO)) and stored at -80°C or –196°C (long 
term storage) in 1 ml aliquots containing 1 - 3 x 106 cells. 
 
2.2.1.2. Transient transfection using calcium phosphate 
Transient transfection assays were carried out using the standard calcium phosphate 
coprecipitation technique. One day prior to transfection, cells were split to reach 70-
80% confluency. Total DNA amounts were equalized using salmon sperm carrier 
DNA and mixed with calcium chloride. BES-buffered saline was then allowed to form 
complexes with the DNA-calcium chloride solution resulting in a fine precipitate of 
positively charged calcium and negatively charged phosphate. This suspension of 
precipitates was added to the culture medium and taken up by the cells. 
 
2.2.1.3. Transient transfection using LipofectamineTM 
One day prior to transfection, cells were split to reach 70-80% confluency. 
Transfections were carried out according to the manufacturer’s instructions in serum-
free medium. DNA and lipofectamine were added in a ratio of 1:2.5 (µg:µl) to the 
cells. For siRNA transfections, cells were incubated with 60 nM siRNA directed 
against Ap-2δ or control siRNA complexed with 4 µl lipofectamine for 72 hours before 
harvesting.  
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2.2.2. Molecular biology 
2.2.2.1. Generation of chemically competent bacteria 
E. coli Top 10 were inoculated into 5 ml of LB medium and grown overnight at 37°C 
and 200 rpm. On the next day, this culture was used to inoculate 200 ml LB medium 
and grown to an optical density (OD) 600 of 0.2 – 0.4. The bacterial suspension was 
cooled down and centrifuged at 2500 rpm for 5 min at 4°C. The pellet was 
resuspended in 100 ml 50 mM CaCl2 and incubated on ice for 20 min. After 
sedimentation, the pellet was resuspended in 20 ml 50 mM CaCl2 containing 15 % 
glycerol and stored in 100 µl aliquots at -80°C.  
 
2.2.2.2. Transformation of chemically competent bacteria 
Competent bacteria were thawed on ice. After addition of the transforming DNA (5 
µl of the ligation or 0.1 – 10 ng plasmid DNA, respectively), the bacteria were 
incubated on ice for 30 minutes before they were subjected to a heat-shock at 
42°C for 30 seconds. The bacteria were then incubated in 500 µl SOC medium in a 
thermocycler at 37°C for one hour. After sedimentation, the bacteria were 
resuspended in 50 µl of the remaining medium and either inoculated in liquid LB 
medium and 100 µg/ml ampicillin or plated on LB agar plates (LB medium 
containing 1% agar and 100 µg/ml ampicillin). The transformed bacteria grew 
overnight into visible colonies. 
 
2.2.2.3. Isolation of plasmid DNA 
Plasmid DNA extraction was based on alkaline lysis. Cultures of 2 ml LB inoculated 
with a colony from an agar plate were grown overnight at 37°C and 200 rpm. Each 
pellet was lysed in 300 µl Buffer 1 and denatured in 300 µl Buffer 2. After 
neutralization with 300 µl Buffer 3, bacterial suspension was centrifuged and DNA 
was precipitated using isopropanol. Then the DNA pellet was washed with 70% 
ethanol and air-dried. The DNA was solved in 30 µl 10 mM Tris-HCl, pH 8.5 and 
subjected to restriction analysis.  
For larger amounts of plasmid DNA, overnight cultures of 100 ml LB inoculated with a 
colony from an agar plate or a recently prepared transformation were grown at 37°C 
and 200 rpm. After sedimentation of the bacteria, the plasmid DNA was extracted via 
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anion exchange using the Nucleobond Xtra Maxi Plus Kit according to the 
manufacturer’s protocol. 
 
2.2.2.4. Isolation of genomic DNA from cultivated cells 
Cultivated cells were trypsinized and pelletized at 1000 rpm for 5 minutes. The pellet 
was lysed in 500 µl lysis buffer containing proteinase K and vortexed thoroughly. The 
lysis was performed overnight at 56°C on a thermocycler. DNA was precipitated by 
the addition of 500 µl isopropanol. The precipitated DNA was sedimented at 13,000 
rpm for 30 minutes at 4°C and subsequently washed with 70% ethanol for 15 minutes 
at 13,000 rpm to clean the pellet from residual ethanol or salts. After air-drying the 
pellet for 10 minutes, the DNA was solved in 50 - 200 µl 10 mM Tris, pH 8.5 (+ 
RNase 100 µg/ml)). For efficient solving, the resuspended DNA was incubated 
overnight at 37°C on a thermomixer. 
 
2.2.2.5. Restriction hydrolysis 
DNA was digested using restriction endonucleases from New England Biolabs. The 
reaction conditions included the enzyme-specific NEB buffers and 1% BSA as well as 
incubation under recommended temperatures. Plasmid DNA was digested with 2 - 5 
U enzymes/µg DNA for 1 - 5 hours and analysed via agarose gel electrophoresis. 
 
2.2.2.6. Purification of DNA 
The purification of DNA from primers after PCR or from reagents after restriction 
hydrolysis was carried out using the High Pure PCR Purification Kit. Briefly, DNA 
was mixed with a high salt concentration buffer and bound to a silica membrane 
while contaminants passed through the column. Impurities were washed away by 
an ethanol-containing buffer and bound DNA was eluted using low salt 
concentration buffer. 
 
2.2.2.7. Dephosphorylation 
After plasmid restriction, the plasmid has two compatible ends that can self-ligate. In 
order to minimize religation and to increase cloning efficiency, 5’-ends of the plasmid 
were dephosphorylated so that only inserts with the essential 5’-phosphate ends can 
ligate with the plasmid. Dephosphorylation was performed using 2 units of shrimp 
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alkaline phosphatase for 1 µg of linearised plasmid. After 2 hours of incubation at 
37°C, the enzyme was inactivated at 65°C for 15 minutes. The DNA was then 
purified from salts and proteins using the High Pure PCR Purification Kit. 
 
2.2.2.8. Generation of blunt ends 
DNA polymerase subunit, the Klenow fragment, catalyzes 5’->3’ synthesis from 
primed single-stranded DNA in the presence of dNTP’s. For the fill-in of recessed 3’ 
termini, 0.3-1 µg of endonuclease-hydrolyzed DNA were incubated with New England 
BioLabs buffer 1, 100 µM dNTP’s and 10 U of DNA polymerase I (Klenow) for 15 min 
at 25°C. After that, the reaction was terminated by the addition of 10 mM EDTA, 
heat-inactivated for 20 min at 75°C and purified using the PCR Purification Kit. 
 
2.2.2.9. Ligation 
For the alignment of two compatible DNA strands, the enzyme ligase connects the 5’-
phosphate end of one strand with the 3’-OH end of the other strand. Purified DNA 
fragments were mixed with 2 µl 10x ligase buffer und 400 units ligase in a final 
volume of 20 µl and incubated at 16°C overnight. 
PCR products were ligated into plasmids using the TOPO® TA cloning kit. The 
ligation was performed according to the manufacturer's instructions. 
 
2.2.2.10. Agarose gel electrophoresis 
DNA fragments were separated according to size using agarose gel electrophoresis. 
Within an electrical field, DNA moves to the anode due to its negatively charged 
phosphate backbone. The velocity of movement is inversely proportional to the 
logarithm of the molecular weight of the DNA fragment. By the addition of the 
intercalating dye ethidium bromide, DNA was visualized under short wave UV light 
(254 nm). The size of the DNA fragments was determined from a parallely loaded, 
defined migration standards. 
Gels were prepared with 0.8 – 2 % (m/v) agarose solved by boiling in 1 x TAE buffer 
and supplied with ethidium bromide (1:10,000; c = 10 mg mL-1). Gels were subjected 
to electrophoresis at 80 volts for 1-2 hours in 1 x TAE. 
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2.2.2.11. Isolation of DNA fragments 
For the isolation of DNA fragments after restriction hydrolysis, DNA was separated 
according to size on an agarose gel. DNA was visualized under longwave UV light 
and the desired band was excised with a scalpel. The DNA was recoverd from the 
agarose block using the Zymoclean Gel DNA Recovery Kit according to the 
manufacturer’s protocol. Agarose was melted at 50°C under slightly acidic conditions 
and bound to a silica membrane. Agarose was removed with a washing step and 
DNA was eluted under alkaline conditions. 
 
2.2.2.12. Photometric quantification of DNA 
The concentration of a DNA solution was determined with a photometer at a 
wavelength of 260 nm. An optical density (OD) of 1 equals a DNA concentration of 
50 µg mL-1. The OD ratio260/280 determines the purity of the DNA where a ratio of > 
1.8 defines pure DNA. A lower ratio indicates contaminations with proteins 
because aromatic amino acids absorb light at 280 nm. 
 
2.2.2.13. Amplification of DNA fragments 
DNA fragments were specifically amplified using the polymerase chain reaction 
(PCR, Mullis et al.,1986). A typical reaction contained 200 ng template DNA, 1x High 
Fidelity PCR buffer, 0.2 mM dNTP’s, 2 mM MgSO4, 0.2 µM each primer and 1 U 
Platinum Taq High Fidelity Polymerase. The PCR was performed in a PCR 
thermocycler under conditions summarized in Table 1. 
 
 
Table 2: PCR cycling conditions 
Cycle step Temperature Time # of cycles 
Initial denaturation 94°C 2 min      1 
Denaturation 94°C 30 sec  
Annealing 60°C 30 sec      30 
Extension 72°C 1 min/kb  
Storage 4°C infinite  
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1.1.1.1. Isolation of RNA 
Total RNA was isolated with the help of Trizol® Reagent. Pellets of trypsinized cells 
grown to 80-90% confluency in a 6-well plate were resuspended in 0.5 ml Trizol and 
incubated for 5 min at room temperature and for 1 min at 30°C. Then, 200 µl of 
chloroform was added, vortexed for 15 sec and incubated for 2 min. The reaction was 
centrifuged for 15 min at 13,000 rpm and 4°C. After that, the colorless upper aqueous 
phase containing the RNA was transferred to a fresh tube and RNA was precipitated 
by adding 500 µl isopropanol. Samples were incubated for 10 min at room 
temperature and then centrifuged for 10 min at 13,000 rpm and 4°C. The pellet was 
washed with 1 ml 70% ethanol and centrifuged for 5 min at 7,500 rpm and 4°C. 
Subsequently, the RNA pellet was air-dried for 5-10 min and redissolved in 50 µl 
DEPC-treated water. Finally, RNA was incubated for 10 min at 55-60°C and stored in 
aliquots at -80°C. 
 
2.2.2.14. RNA gel electrophoresis 
Agarose gel (1.2%) was prepared using Mops buffer and 5% formaldehyde. Prior to 
electrophoresis, RNA was boiled with 10 µl FDP and 2 µl loading buffer in a total 
volume of 20 µl. Gels were subjected to electrophoresis at 100 volts for 30 min in 1 x 
Mops. 
 
2.2.2.15. cDNA synthesis  
Total RNA was isolated with the help of Trizol Reagent (see Isolation of RNA) and 
cDNA synthesis was performed using the SuperScript Reverse Transcription kit. 500 
ng - 2 µg RNA were mixed with 1 µl Oligo(dT) and 1 µl dNTPs (10 mM) to a final 
volume of 13 µl and incubated at 65 °C for 5 minutes. This was followed by the 
addition of 4 µl reverse transcriptase buffer, 1 µl DTT, 1 µl RNAse OUTTM and 1 µl 
Superscript III reverse transcriptase. cDNA synthesis was carried out at 50°C for one 
hour followed by heat inactivation at 70°C for 15 minutes. 
 
2.2.2.16. Quantitative real-time PCR 
Gene expression was monitored by quantitative real-time PCR using SYBR GreenER 
qPCR SuperMix (Invitrogen) in an ABI Prism 7900 (Applied Biosystems). The SYBR 
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GreenER qPCR SuperMix allows normalization with ROX reference dye which 
adjusts for non-PCR-related fluctuations in fluorescence between reactions. Each 
individual analysis was performed in triplicates. The Ct (cycle threshold) value 
defines the number of cycles required for the fluorescence signal to exceed the 
background. These values are proportional to the amount of DNA. Expression values 
were normalized to the mean of housekeeper Hprt or Gapdh. 
 
Table 3: Quantitative real-time PCR reagent mix 
Reagent Volume 
cDNA 1.5 µl 
10 mM Primer mix (forward and reverse) 2 µl 
SYBR GreenER qPCR SuperMix 5 µl 
DEPC-treated water ad 10 µl 
 
 
Table 4: Quantitative real-time PCR cycling conditions 
Cycling step temperature time # of cycles 
UDG incubation 50°C 2 min 1 
UDG inactivation/ 
DNA polymerase activation 
95°C 10 min 1 
Denaturation 95°C 15 sec 40 
Annealing 60°C 1 min 40 
       UDG: uracil DNA glycosylase 
 
Melting curve analysis was performed for each set of primers to avoid primer dimer 
formation. 
 
2.2.2.17. Statistical methods 
Statistical significance was calculated using the students’ t-test. A p-value less than 
0.05 was considered to be significant. (* = p < 0.05; ** = p < 0.005; *** = p < 0.0005) 
 
2.2.2.18. Sequencing 
DNA was sequenced according to Sanger and performed by Entelechon 
(Regensburg). DNA sequences were evaluated using the sequence alignment tool 
HUSAR (Heidelberg UNIX Sequence Analysis Resources) provided by the DKFZ 
(Heidelberg), the data bases NCBI (www.ncbi.nlm.nih.gov/), and Ensembl 
(www.ensembl.org/index.html). 
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2.2.2.19. Affymetrix microarray procedures 
RNA of 15 Ap-2δ-/- and wild-type E15 posterior midbrains was purified using the 
RNeasyMini-kit from Qiagen. 2.5 µg RNA was transcribed into biotinylated cRNA 
according to the Affymetrix standard protocol version 2. After purification and 
fragmentation, cRNA was hybridized to Affimetrix GeneChip Mouse Genome xY 2. = 
ArraysHG-U133Plus_2.0 microarrays (Affymetrix Inc.). The microarray data have 
been released into the GEO-database (Accession Number GSE27296). 
 
 
2.2.3. Biochemistry 
2.2.3.1. Preparation of protein samples from adherent cells 
Cells were washed and scraped off in ice cold PBS. Cells were pelleted by 
centrifugation at 3,000 rpm for 3 minutes at 4°C and lysed with RIPA buffer or 
coimmunoprecipitation buffer on ice for 30 min in the presence of protease inhibitor. 
The lysates were cleared by centrifugation for 15 minutes at 12,000 rpm.  
 
2.2.3.2. Protein quantification 
Protein was quantified using the Bradford dye assay employing coomassie blue and 
a BSA (bovine serum albumine) standard comprising five concentrations (0.25 µg, 
1.25 µg, 2.5 µg, 5 µg and 7.5 µg). Absorption measurements were determined 
photometrically by an ELISA reader. Protein concentrations were calculated from 
plotted standard curve. 
 
2.2.3.3. SDS-PAGE/Western Blot 
SDS-PAGE separates proteins based on their weight and electrical properties as 
they migrate through a polyacrylamide gel. Denatured cell extracts as well as a 
prestained molecular weight marker were loaded onto a polyacrylamide gel and 
separated by electrophoresis at 45-65 mA in 1x Laemmli running buffer.  
Proteins were then immobilized on a polyvinylidene fluoride (PVDF) membrane with 
the semi-dry blotting method in western transfer buffer by applying an electrical field 
(11 V for 1,25 hours). In order to reduce non-specific protein interactions between 
the membrane and the antibody, free binding sites were blocked with 5% non-fat dry 
milk in PBST for 1-3h. Proteins were detected by incubation with specific antibodies 
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in 5% non-fat dry milk in PBST overnight at 4°C and with secondary HRP conjugated 
antibodies in PBST for 1 hour at room temperature. Bound antibodies were 
visualized with the help of chemiluminescence and autoradiography films according 
to the manufacturer’s protocol. 
 
2.2.3.4. Protein staining with Coomassie Brilliant Blue R250 
The PVDF membrane was stained with Coomasie Blue for 2 minutes and then 
incubated with Destain solution for approximately 15 minutes, until the background 
was reduced and blue bands were clearly visible. 
 
2.2.3.5. Immunofluorescence 
Transfected cells were fixed with 4% paraformaldehyde for 10 minutes at room 
temperature. Permeabilization was achieved with 0.2% Triton-X in PBS for 5 
minutes. Free binding sites were blocked with 1.5% BSA in PBS for 1 hour. Anti-
Nfatc2 and anti-Ap-2δ antibodies were diluted 1:400 in PBS containing 1.5% BSA 
and incubated overnight at 4°C. Unbound antibody was washed away with PBS. 
Proteins were detected with Alexa Fluor 488- and Alexa Fluor 595-conjugated 
antibodies diluted 1:400 in PBS containing 1.5% BSA for 1 hour at room 
temperature. Cell nuclei were stained with Hoechst 33342 diluted 1:500 in PBS 
containing 1.5% BSA for 5 minutes. Analysis of immunofluorescence was performed 
with a fluorescence microscope. 
 
2.2.4. Functional studies 
2.2.4.1. Luciferase assay 
Neuro2a cells were co-transfected with the reporter plasmids pGl3-Pou4f3 -2.8 kb, 
pGl3-Bhlhb4 -6 kb, pGl3-Bhlhb4 -0.5 kb and the expression plasmid pSG5-Ap-2δ. 
Cells were lysed 48 hours later for 5 minutes in lysis buffer. After sedimentation, 10 µl 
of the supernatant were transferred to a white luminometer 96-well plate. 
Luciferase (LUC) activity was assayed with 50 µl assay buffer for 1 second as 
recommended by the manufacturer in the Luminometer Centro LB 960. Relative light 
units were normalized to protein concentration using the Bradford dye assay. All 
experiments were repeated at least five times. 
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2.2.4.2. Chromatin immunoprecipitation (ChIP) 
Expression plasmid transfected Neuro2a cells were grown 48 hours before 
harvesting for ChIP. Aliquots of 2x106 cells were cross-linked with 1% formaldehyde 
for 7 minutes and incubated with 0.1 M glycine for 5 minutes at room temperature 
with intensive shaking in a thermomixer (1100rpm). After two rounds of washing with 
1 ml cold PBS, cells were resuspended in 200 µl SDS Lysis Buffer and sonicated for 
3 cycles consisting of 7.5 minutes (30 seconds “ON”/30 seconds “OFF”).  
Immunoprecipitation mix contained 50 µg sonicated DNA, 2 µg salmon sperm DNA, 
and protease inhibitors in ChIP dilution buffer in a final volume of 400 µl. Specific 
antibodies against Ap-2δ, Nfatc2, HA and IgG as a negative control were added to 
the probes and incubated for 2-4 hours at 4°C at constant rotation. After that, 25 µl of 
each protein A and protein G coupled Dynabeads® (Invitrogen, Karlsruhe, Germany) 
were washed with dilution buffer and added to the probes for overnight incubation. 
On the next day, protein/DNA complexes were washed three times with 500 µl wash 
buffer, eluted for 1-2 hours using 100 µl elution buffer, reverse crosslinked and 
Proteinase K digested under the following conditions: 
 
Table 5: Reverse crosslink 
Temperature Time 
55°C 2 hours 
65°C 6 hours 
75°C 2 hours 
4°C infinite 
 
 
Purified DNA specimens were subjected to real-time PCR using SYBR GreenER 
qPCR SuperMix as indicated above (qRT-PCR). Amplicons were normalized to the 
DNA immunoprecipitated with antibody to histone H3 (Abcam, Cambridge, UK). 
Values were displayed as percent H3 with H3 occupancy arbitrarily set to 100%.  
 
2.2.4.3. Annealing of oligonucleotides for EMSA 
Double-stranded oligonucleotides were prepared by incubating 30 µg of single-
stranded, complementary olidonucleotides with 1x NEB buffer 1 in a final volume of 
100 µl at 85°C for 10 minutes and slowly cooled down to room temperature. 
Annealed oligonucleotides were precipitated with 4 volumes 100% ethanol, 0.1 
volume 3 M NaAc and 1 M MgCl2 for at least 30 minutes at -80°C followed by 
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centrifugation at 13000 rpm for 30 minutes at 4°C. Pellets were resuspended in 60 µl 
water. 
 
2.2.4.4. Radioactive labeling of oligonucleotides 
100 ng of double-stranded oligonucleotides were 5’-labeled by Klenow with 50 µCi [α-
32P] CTP. Labeling reactions were incubated at 30°C for 30 minutes. ProbeQuant G-
50 Micro Columns were used according to the manufacturer’s instructions to remove 
unincorporated [α-32P] CTP. 
 
2.2.4.5. EMSA 
The TNT-coupled reticulocyte extract (Promega) was employed to generate in vitro 
translated Ap-2δ protein. Protein was diluted in  EMSA binding buffer and incubated 
with approximately 0.8 ng of the 32P-labeled oligonucleotide probe in at room 
temperature for 20 min. Separation of complexes was achieved on 5% 
nondenaturing polyacrylamide gels in 0.25 × TBE running buffer at room 
temperature. After electrophoresis, gels were dried and subjected to autoradiography 
at −80°C. To demonstrate the presence of Ap-2δ in the shifted complexes, samples 
were incubated with α-Ap-2δ and rabbit α-IgG antibodies. 80-fold excess of unlabeled 
oligo served as a competitor. 
 
2.2.4.6. Expression and purification of recombinant GST fusion proteins in E. coli 
BL21 
Chemically competent E. coli BL21 were transformed with a plasmid coding for a N-
terminal glutathione-S-transferase fused to the Ap-2δ transactivation domain. One 
colony was used to inoculate 40 ml of LB medium containing ampicillin. This 
overnight culture was diluted 1:10  and grown to an OD 600 of 0.7. The expression of 
the fusion protein was induced by adding 1 mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG). For control reasons, samples were collected before and 
after IPTG addition. After 2-3 hours, the bacteria were pelleted and resuspended in 
10 ml lysis buffer. Lysis was achieved upon 3 repeated freeze-thaw cycles. Lysed 
bacteria were pelleted and supernatant containing recombinant protein was aliquoted 
and stored at -20°C. Again, a control sample was drawn from the supernatant. 
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Efficiency of protein expression and purification was analyzed by subjecting control 
samples to SDS-PAGE. 
 
2.2.4.7. GST Pulldown 
Glutathione Sepharose was precleared by washing 3 times with PBS. 50 µl of the 
precleared sepharose were combined with 15 µl GST alone or 250 µl GST-Ap-2δ, 
respectively, and incubated for one hour. The sepharose was washed three times 
with 1 ml pulldown interaction buffer and resuspended in 500 µl of the same buffer. 
To this sample, 5 µl of in vitro translated Ap-2δ protein was added and binding was 
facilitated by incubating for 1 hour at room temperature under constant rotation. After 
three washing steps with 1 ml interaction buffer, sepharose was resuspended in 20 µl 
Roti®-load, boiled at 95°C for five minutes and electrophoresed in a 15% 
polyacylamide gel. 
 
2.2.4.8. Co-immunoprecipitation 
Cells were transiently transfected with pCMX-Ap-2δ and pCMX-Nfatc2 and harvested 
after 48 hours in Co-IP lysis buffer. Immunoprecipitation was performed overnight 
with 100 – 300 µg protein lysate, 3 µl of anti-Ap-2δ antibody and either 40 µl 
immunoprecipitation matrix (Exacta Cruz BTM, Santa Cruz, Heidelberg) or 25 µl of 
each protein A and protein G coupled Dynabeads®. After three washing steps with 
Co-IP lysis buffer, the pellet was resuspended in 2x Roti®-load and boiled for five 
minutes. The supernatant was electrophoresed and immunoblotted as described 
above using anti-HA.11 or anti-Nfatc2 antibody in a 1:5000 dilution. The HRP-
conjugated Exacta Cruz B detection reagents or conventional HRP-conjugated 
antibodies were used as secondary antibodies. 
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3. Results 
 
The following work was carried out in collaboration with PD Dr. Markus Moser 
(Martinsried). The results of project 3.1 have been published in PlosOne. “Ap-2δ is a 
crucial transcriptional regulator of the posterior midbrain” (Hesse et al., 2011). 
A manuscript for publication on the findings of project 3.2 is currently in preparation. 
“Transcription factors Ap-2δ and Nfatc2 interact to synergistically regulate target 
gene transcription”. 
 
3.1. Ap-2δ is a crucial transcriptional regulator of the posterior 
midbrain 
3.1.1. Loss of colliculus inferior in Ap-2δ-deficient mice 
In an effort to elucidate the role of Ap-2δ in vivo, the Tcfap2d gene was inactivated in 
mice by Markus Moser (MPI Martinsried). Owing to the brain-specific expression of 
Ap-2δ, embryonic lethality of the mice was not expected and thus, we did not choose 
to construct an inducible null-allele. The constitutive Tcfap2d-deficient mice were 
generated by gene targeting. The first exon of the Tcfap2d gene was deleted by 
insertion of a β-galactosidase-neomycin cassette. Heterozygous Ap-2δ mice 
(Tcfap2d +/-) did not exhibit an overt phenotype and produced offspring. In contrast 
to other established Tcfap2 knockouts (Eckert et al., 2005) (except for Tcfap2e), Ap-
2δ-deficient mice (Tcfap2d-/-) completed embryogenesis and were vital. 
Further analysis of these mice addressed the question of whether loss of Tcfap2d 
affects brain morphology. As already comprehensively described in the introduction, 
Ap-2δ expression is mainly restricted to the brain, and to a lesser extent to retina and 
myocardium. The brains of 6 weeks old Tcfap2d-/- mice had developed into a 
normally organized forebrain and hindbrain. However, analysis of sagittal brain 
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sections of Ap-2δ mutant mice revealed the absence of a structure of the posterior 
midbrain, the colliculus inferior (Fig. 5a, b).  
 
        Markus Moser (Hesse et al., 2011) 
 
Figure 5: Histological differences between wild-type (+/+) and Ap-2δ-deficient (-/-) posterior 
midbrains (a, b) Midbrain paraffin sections of 1.5 months old mice were stained with hematoxylin-
eosin. The colliculus inferior (Ci) is missing in Ap-2δ-deficient mice (arrow). (c-f) Labeling of Ap-2 
expression with Ap-2δ (c, d) and Ap-2α (e, f) -specific antibodies on sagittal sections from 3 weeks old 
mice midbrains. Ap-2δ antibody reactivity is concentrated in the colliculus inferior. The colliculus 
superior (Cs) and the dorsal thalamus (dT) also stain positive for Ap-2δ. Ap-2α expression can be 
detected in the colliculus superior and the cerebellum (Cb) of wild-type animals. In Ap-2δ-deficient 
brains that lack the colliculus inferior, Ap-2α is expressed throughout the entire mesencephalon. C = 
cortex 
 
Ap-2δ expression was visualized with the help of an isoform-specific Ap-2δ rabbit 
antiserum kindly provided by PD Dr. Markus Moser. In adult wild-type brains, Ap-2δ 
Ci 
Cs 
dT Cb 
C 
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is expressed in the colliculus inferior and, to a lesser extent, the dorsal thalamus and 
the colliculus superior (Fig. 5c). Immunostaining of sagittal brain sections from 
Tcfap2d-/- mice with the Ap-2δ antibody did not produce any signal indicating the 
absence of Ap-2δ protein (Fig. 5d). Ap-2α is strongly expressed in the colliculus 
superior and the cerebellum which are structures of the anterior dorsal midbrain. Ap-
2α is not co-expressed with Ap-2δ in the colliculus inferior (Fig. 5e). Of note, Ap-2α 
expression extends throughout the entire mesencephalon of Tcfap2d-/- mice 
substantiating the complete absence of the colliculus inferior (Fig. 5f). 
 
3.1.2. Ap-2δ-deficient mice lack colliculus inferior as a result of apoptosis  
Ap-2 transcription factors are involved in programming cell survival during 
embryogenesis since disruption of Ap-2 function leads to massive apoptosis (Moser 
et al., 1997). Therefore, it was analyzed if the colliculus inferior was lost as a result of 
increased cell death in the developing brain. The expression of the apoptotic marker 
activated caspase 3 was immunohistochemically investigated in embryonic brains 
between E13 and E17. Wild-type and Ap-2δ-deficient brains showed no signs of 
apoptosis at E13. At E15, however, first apoptotic cells stained positive for activated 
caspase 3 in the posterior midbrain of Ap-2δ-deficient mice. The number of cells 
undergoing apoptosis was dramatically increased by E17 in the posterior midbrain of 
Ap-2δ mutants. Control embryos did not experience enhanced apoptosis at neither 
developmental stage (Fig. 6, middle and right column). Labeling of consecutive wild-
type sections with Ap-2δ antibody mapped Ap-2δ expression to the same region of 
the posterior midbrain where apoptotic cell death was observed in Ap-2 mutant mice 
(Fig. 6, right and left column). These data demonstrate that Ap-2δ deficiency leads to 
a dramatic increase in apoptosis and subsequent degradation of the posterior 
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midbrain and assign a role for Ap-2δ in cell survival and maturation of the posterior 
midbrain.  
 
 
     Markus Moser (Hesse et al., 2011) 
 
Figure 6: Ap-2δ-deficiency leads to enhanced apoptosis in the posterior midbrain. (a) Using 
immunolabeling on coronal sections of embryonic brains of different developmental stages (E13-E17), 
Ap-2δ expression (left column) and apoptosis (middle and right column) were visualized with an Ap-2δ 
antibody or an activated caspase 3 antibody, respectively. At E15, single apoptotic cells stained 
positive in the posterior midbrain of Ap-2δ mutant mice (arrows). By E17, the number of apoptotic cells 
was dramatically increased in Ap-2δ-deficient brains. Very right column: Sectional plane through the 
brain. 
 
3.1.3. Ap-2δ-regulated genes in the developing posterior midbrain  
To dissect the mechanisms that are involved in posterior midbrain development 
under the control of Ap-2δ, Ap-2δ-specific target genes were identified using 
microarray analysis. Extraction of RNA was performed on E15.5 before the onset of 
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massive apoptosis. Fifteen wild-type and fifteen Tcfap2d-/- posterior midbrains were 
used for RNA preparation and pooled for the comparison of expression patterns by 
microarray analysis. Ap-2δ-deficient posterior midbrains showed a differential 
expression of 12 genes compared to wild-type expression levels (Table 6).  
 
Table 6: In the posterior midbrain, knockout of Tcfap2d resulted in differential expression of 12 genes 
at E15.5. 
 
No. of 
hits 
Gene Name Gene Factor (ko vs. wt 
signal log ratio) 
1 Tcfap2d Transcription factor Ap-2δ -1.84 
4 Mef2c Myocyte enhancer factor 2c 
-1.34 
-1.33 
-1.43 
-1.48 
1 Bhlhb4 
Basic helix-loop-helix domain 
containing, class B4 
-1.70 
1 Pou4f3 
POU domain, class 4, transcription 
factor 3 
-2.08 
1 Pitx2 
Paired-like homeodomain 
transcription factor 2 
-1.28 
3 Rgs4 Regulator of G-protein signaling 4 
1.78 
1.82 
1.99 
1 Myh8 
Myosin, heavy polypeptide 8, 
skeletal muscle, perinatal 
-2.09 
1 Cxcl12 
Chemokine (C-X-C motif) ligand 
12 
-1.60 
1 Ndst4 
N-deacetylase/N-sulfotransferase 
(heparin glucosaminyl)4 
-1.93 
1 Slap Scr-like adaptor protein -2.09 
1 Rdh9 Retinol dehydrogenase 9 1.65 
1 Hjurp 
Holliday junction recognition 
protein 
-1.38 
1 Fgf3 Fibroblast growth factor 3 -1.66 
 
To confirm differential expression detected via microarray analysis, quantitative RT-
PCR analysis from total RNA samples isolated from the midbrains of E15.5 embryos 
was performed. Of the 12 candidate genes, 10 genes showed a reduced expression 
in Ap-2δ-deficient midbrain compared to wild-type tissue (Fig. 7). Interestingly, the 
  Results 
53 
 
 
expression of two genes, Rdh9 and Rgs4, was increased in the absence of Ap-2δ 
suggesting that Ap-2δ is also involved in transcriptional repression. 
 
Figure 7: Validation of microarray data by quantitative real-time PCR. RNA samples isolated from 
the midbrains of E15.5 wildtype and Tcfap2d-/- embryos were subjected to qRT-PCR using target-
specific primers. Bars are displayed as relative expression of candidates in Tcfap2d-/- embryos 
compared to wildtype embryos (Hesse et al., 2011). 
 
Notably, among the identified putative Ap-2δ target genes were the four transcription 
factors Pitx2 (paired-like homeodomain transcription factor 2), Mef2c (myocyte 
enhancer factor 2C), Bhlhb4 (basic helix-loop-helix domain containing, class B4), and 
Pou4f3 (POU domain, class 4, transcription factor 3). These transcription factors play 
fundamental roles during development (Gage et al., 1999; Lin et al., 1996) in 
particular the development and survival of sensory neurons (Bramblett et al., 2004; 
Xiang et al., 1998). Wild-type brains from E15.5 were used to verify expression of 
those transcription factors in the midbrain using whole mount in situ hybridizations 
(Fig. 8). Ap-2δ deficiency clearly abrogates expression of Pitx2, Mef2c, Bhlhb4 and 
Pou4f3 specifically in the midbrain, since other brain structures such as the forebrain 
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and thalamus continue to express Mef2c and Pitx2, respectively, in the absence of 
Ap-2δ (Fig. 8). 
 
 
Figure 8: Loss of Pitx2, Mef2c, Bhlhb4, and Pou4f3 expression in midbrain of Tcfap2d-deficient 
mice. Pitx2, Mef2c, Bhlhb4 and Pou4f3 expression was detected with the help of in situ hybridizations. 
Wild-type (+/+) and Tcfap2d-deficient (-/-) brains from E15 were probed with corresponding cDNA 
probes. The figure displays lateral (top), dorsal (middle) and ventral (below) views. Loss of Ap-2δ 
abolished expression of candidate targets in midbrain (arrows) (Hesse et al., 2011). 
 
 
3.1.4. Ap-2δ transactivates Pou4f3 and Bhlhb4 promoter  
The regulatory potential of Ap-2δ on the transcription of Bhlhb4 and Pou4f3 was 
investigated with the help of transient transfection experiments using candidate 
promoter-driven luciferase constructs were conducted. Luciferase reporters were 
generated containing 6 kb and 500 bp fragments of the Bhlhb4 promoter (Bhlhb4 -
6kb and Bhlhb4 -0.5kb, respectively) and a 2.8 kb fragment of the Pou4f3 promoter 
(Pou4f3 -2.8kb) (Fig. 9A) upstream of the firefly luciferase reporter gene.  
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Figure 9: Ap-2δ functions as a transactivator of Pou4f3 and Bhlhb4 promoter 
(A) Schematic presentation of reporter plasmids containing various lengths of 5’-flanking regions of 
Ap-2δ candidate target genes placed upstream of a luciferase reporter gene. 
(B) Western Blot showing endogenous Ap-2δ expression in Neuro2a cells. Expression could be 
increased by transfection with the expression plasmid pSG5-Ap-2δ. β-actin was used as a loading 
control and HepG2 as negative control. 
(C) Neuro2a cells were co-transfected with reporter plasmids Pou4f3-2.8kb, Bhlhb4-6kb, and Bhlhb4-
0.5 kb together with an Ap-2δ expression plasmid or the empty plasmid as a control. Luc reporter 
constructs were activated by Ap-2δ. Luciferase units are displayed relative to total protein and show 
the mean ± s.e.m. of three independent transfections. Promoter-less pGl3-basic vector-only 
transfections were set at 1. p-values show significant increase to control plasmid-transfected cells. * = 
p < 0.05 (Hesse et al., 2011). 
 
Transcriptional activation of these reporters was monitored following transfection in 
Neuro2a cells which endogenously express Ap-2δ. Transfection with an Ap-2δ 
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expression plasmid further increased expression (Fig. 9B). HepG2 cells do not 
express Ap-2δ and were used as a control. Cell lysates were collected and luciferase 
activity was measured 48 hours after transfection. All three reporter constructs were 
activated for more than 2.5-fold upon co-transfection of an Ap-2δ expression plasmid. 
This activation lies within the activating potential of Ap-2 proteins (Fig. 9C). The 
promoter-less pGl3-basic vector was used as a control. 
 
 
3.1.5. In vivo promoter occupancy of Bhlhb4 and Pou4f3 by Ap-2δ 
3.1.5.1. Optimization of ChIP conditions  
To determine if Ap-2δ directly binds to and activates Bhlhb4 and Pou4f3, chromatin 
immunoprecipitation (ChIP) followed by quantitative real-time PCR was performed.  
 
 
 
Figure 10: Chromatin fragmentation characterization 
Agarose gel analysis of sheared chromatin obtained with the BioruptorTM (Diagenode). DNA and 
proteins of Neuro2a cells were crosslinked with 1% formaldehyde. Each sample consists of 2 x 10
6
 
cells in a total volume of 200 µl lysis buffer. Samples were sonicated for 3 cycles consisting of 7.5 
minutes (30 seconds “ON”/30 seconds “OFF”) and cross-linking was reversed. Lane 1 contains a 1kb 
DNA ladder. 
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ChIP is a powerful tool to study if a protein of interest is localized to a specific 
genomic locus in vivo. Sheared chromatin fragments are enriched with antibodies 
specific for the protein of interest which has been crosslinked to the DNA before. 
Quantitative real-time PCR is then employed to detect specific DNA sequences in 
the enriched chromatin. 
Chromatin DNA was fragmented to an average apparent size of 200 to 500 bp (Fig. 
10). Samples were sonicated for 3 cycles consisting of 7.5 minutes (30 seconds 
“ON”/30 seconds “OFF”) and submitted to cross-linking reversion. Subsequently, 
chromatin fragmentation was judged by agarose gel electrophoresis (Fig. 10).  
With the help of algorithm rVista and manual sequence analysis, potential Ap-2 
binding sites were identified on genomic loci of Bhlhb4 and Pou4f3 within 3 kb 
upstream of the transcriptional start site (TSS).  
 
 
Figure 11: Schematic presentation of Bhlhb4 and Pou4f3 genomic loci. With the help of algorithm 
rVista and manual sequence analysis three potential Ap-2 binding sites were identified in the Bhlhb4 
promoter and one potential binding site in the Pou4f3 promoter. Binding sites are displayed as red 
bars, primers are depicted as arrows. Numbers indicate location relative to TSS. Ex = exon  
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This resulted in the detection of two regions with three putative binding sites in the 
Bhlhb4 promoter. One sequence in the Pou4f3 promoter was of special interest 
because it consists of a central TGA spacer flanked by GCC and GGG triplets (Fig. 
11). Zhao et al. (Zhao et al., 2003) could show that Ap-2δ specifically binds to a 
sequence with TGA as the preferred central 3 bp spacer between the palindromic 
GCC motifs. Primers were designed to specifically amplify those putative binding 
sites. 
 
3.1.5.2. Ap-2δ associates to Bhlhb4 and Pou4f3 promoters in vivo 
Neuro2a cells endogenously express Ap-2δ but showed a strong increase in 
expression after transfection with an HA-tagged Ap-2δ expression plasmid (Fig. 12A). 
Chromatin of HA-tagged Ap-2δ-transfected Neuro2a cells or untransfected cells was 
immunoprecipitated with an α-HA/Ap-2δ antibody or α-IgG antibody as a negative 
control. The ChIP assay demonstrated a significant level of Ap-2δ binding in the 
genomic locus of Bhlhb4 at the two previously identified binding sites located -1.8 kb 
and -300 bp upstream of the transcriptional start site (TSS) (Fig. 12B/C). Moreover, 
Pou4f3 promoter occupancy by Ap-2δ was observed at the conserved recognition 
sequence 2.6 kb upstream of the TSS (Fig. 12D). In contrast, the association of Ap-
2δ to these sites was not evident in untransfected cells or after immunoprecipitation 
with the control antibody (Fig. 12B-D). 
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Figure 12: Ap-2δ occupies Bhlhb4 and Pou4f3 promoter in vivo 
(A) Western blot analysis shows Ap-2δ expression and detection of the HA-tag as a control in protein 
extracts of untreated Neuro2a cells or transfected with an HA-tagged Ap-2δ expression plasmid. β-
actin was used as a loading control. 
(B/C/D) DNA from untransfected and  HA-Ap-2δ transfected Neuro2a cells immunoprecipitated with 
antibodies to HA or IgG was quantified by real-time PCR using primers flanking the Bhlhb4 (-1.6 kb 
and -300 bp) and the Pou4f3 (-2.6kb) genomic loci upstream of the transcriptional start site (TSS). 
(B/C) Ap-2δ is associated to specific regions of the Bhlhb4 promoter. Sites are located 1.8 kb and 300 
bp upstream of the TSS. (D) Pou4f3 promoter is bound by Ap-2δ  2.8 kb upstream of the TSS.  Bars 
display mean abundance ± s.e.m. relative to histone H3 (internal control) from triplicates. P-values 
indicate significant differences from HA-Ap-2δ transfected Neuro2a cells precipitated with an anti-HA 
antibody compared to non-transfected Neuro2a cells or IgG treated lysates. ** = p < 0.005; * = p < 
0.05 (Hesse et al., 2011) 
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3.1.6. Pou4f3 promoter is a direct target of Ap-2δ 
Binding and transactivation by Ap-2 proteins is only achieved at recognition sites of 
the sequence GCCN3/4GGC or GCCN3/4GGG. A sequence containing TGA as the 
preferred central 3 bp spacer which facilitates Ap-2δ binding is present in the Pou4f3 
promoter at the site demonstrated to be occupied by Ap-2δ. Thus, electrophoretic 
mobility shift assays (EMSA) were conducted to evaluate the direct binding of Ap-2δ 
to this sequence. This sensitive method is based on the fact that complexes of 
protein and DNA migrate through a non-denaturing polyacrylamide gel more slowly 
than free double-stranded oligonucleotides. The expression vector pCMX-Ap-2δ 
contains a T7 promoter which enables the in vitro translation of Ap-2δ. For 
visualization, the oligonucleotides being composed of the putative binding sites were 
32P-labeled. The EMSA assays demonstrated direct binding of Ap-2δ protein (pCMX-
Ap-2δ) to both oligonucleotides containing the optimized Ap-2 binding site from Zhao 
et al. (Zhao probe) as positive control or the native binding site of the Pou4f3 
promoter (Pou wt probe) (Fig. 9A, lanes 2 and 7) (Zhao et al, 2003). The supershift 
obtained after addition of an α-Ap-2δ antibody but not an unrelated IgG antibody 
indicates the presence of Ap-2δ protein in the retarded complex (Fig. 13A, lanes 3 
and 8; Fig. 13B, lanes 3 and 4). The signal of the Ap-2δ/DNA complex was 
antagonized by an 80-fold molar excess of unlabeled oligo (Zhao/Pou wt 
competitor)(Fig. 13A, lanes 4 and 5; 9 and 10).  
The specificity of binding was manifested by introduction of mutations in the central 3 
nucleotides between the palindromic GCC motifs (core sequence Pou wt: GCC TGA 
GGG, mutated forms Pou mt1: GCC AGT GGG, Pou mt2: GCC GTT GGG). Ap-2δ 
binding was abrogated upon mutagenesis of the consensus sequence demonstrating 
high specificity (Fig. 13B).  
  Results 
61 
 
 
 
 
 
  Results 
62 
 
 
 
 
 
Figure 13: Direct binding of Ap-2δ to specific consensus sequence within Pou4f3 promoter 
(A) EMSA assay with 
32
P-labeled oligonucleotide containing the specific binding site of the Pou4f3 
promoter (Pou wt) or an optimized Ap-2δ binding site (Zhao) and in vitro translated Ap-2δ protein. 
Addition of an α-Ap-2δ antibody but not an unspecific control antibody produced a supershift. 
Competition experiments were performed using an 80-fold excess of unlabeled oligonucleotide. pCMX 
= empty vector (control), pCMX-Ap-2δ = Ap-2δ cDNA; anti-Ap-2δ = Ap-2δ antibody, anti-rIgG = IgG 
antibody (control), Zhao/Pou wt competitor = unlabeled oligos  
(B) EMSA assay with wildtype binding site of the Pou4f3 promoter (core sequence: GCC TGA GGG) 
or mutated forms (Pou mt1: GCC AGT GGG, Pou mt2: GCC GTT GGG). Ap-2δ binding was 
abrogated upon mutagenesis of the consensus sequence (Hesse et al., 2011). 
(C) EMSA was performed with an oligonucleotide containing a binding site of the Bhlhb4 promoter or 
the optimized Ap-2δ binding site. In vitro translated Ap-2δ protein did not bind to the oligonucleotide 
derived from the Bhlhb4 promoter. 
n.s. = not specific 
 
In contrast to that, complex formation between in vitro translated Ap-2δ (pCMX-Ap-
2δ) and oligonucleotides containing binding sites of the Bhlhb4 promoter could not be 
detected. Fig. 13C shows an EMSA with the ACC TGA GGG binding site (Bhlhb4 -
300 bp) as an example. Thus, we assume that Ap-2δ might associate with and 
activate the Bhlhb4 promoter through a complex with cofactors and interaction 
partners. 
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3.1.7. Pou4f3 target genes are downregulated upon Ap-2δ ablation 
The downregulation of Pou4f3 transcription after Tcfap2d knockout was 
demonstrated with the help of microarray analysis and qRT-PCR (Table 6, Fig.7) 
Whether Ap-2δ deficiency also had an effect on Pou4f3 target genes was examined 
next (Clough et al., 2004; Hertzano et al., 2007). Pou4f3 is expressed in a subset of 
cells of neuronal origin and all hair cells of the inner ear. It has been described to 
activate the promoter of brain-derived neurotrophic factor (Bdnf; (Clough et al., 2004). 
This neurotrophin is expressed in sensory hair cells of inner ear epithelia and is 
essential for normal afferent innervation of the inner ear (Pirvola et al., 1992). 
Transcript levels of Bdnf as well as Calbindin2 were significantly downregulated in 
samples of Pou4f3-deficient inner ears compared to wildtype (Hertzano et al., 2007). 
Calbindin2 is a calcium-binding protein expressed in the cochlear nucleus (Friedland 
et al., 2006). It may be implicated in auditory processing due to upregulation of 
expression in aging animals and models of hearing loss (Fuentes-Santamaria et al., 
2003; Zettel et al., 1997). The LIM domain transcription factor Lhx3 is a hair cell-
specific gene expressed in all hair cells of the auditory and vestibular system. It was 
identified as an in vivo target gene of Pou4f3 by a microarray approach with inner 
ears of Pou4f3 mutant and wildtype mice (Hertzano et al., 2007). 
RNA from posterior midbrain samples of wild-type and Tcfap2d-/- mice was 
subjected to cDNA conversion and subsequent qRT-PCR. In Ap-2δ mutant samples, 
mRNA levels of Pou4f3 were reduced for more than 80% compared to control levels. 
Consistently, the Pou4f3 target gene Bdnf was also significantly downregulated and 
Calbindin2 expression was slightly reduced. The gene encoding transcription factor 
Lhx3, another Pou4f3 target, was not affected by the absence of Ap-2δ (Fig. 14). 
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Figure 14: Relative mRNA expression of Pou4f3-regulated genes in Ap-2δ-deficient brains. 
qRT-PCR on posterior midbrains of wild-type and Tcfap2d knockout mice at E15 with 4-6 repetitions. 
HPRT served as reference gene. p-values indicate significant differences of targets in the posterior 
midbrains of Tcfap2d knockout mice compared to wild-types.*** = p < 0.0005; * = p < 0.05. Transcript 
levels of Bdnf and Calbindin2 were reduced, whereas an alteration in expression of Lhx3 cannot be 
observed upon Ap-2δ deficiency. Calb2 = Calbindin2 (Hesse et al., 2011) 
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3.2. Transcription factors Ap-2δ and Nfatc2 interact to 
synergistically regulate target gene transcription 
 
A preliminary step in understanding protein function is to determine which proteins 
interact with each other, thereby identifying the relevant biological pathways. Up to 
date, only one interaction partner for Ap-2δ has been identified. Tan et al. 
demonstrated in 2008 an interaction between Ap-2δ and Ash2l and showed that 
these proteins cooperatively activate Hoxc8 (Tan et al., 2008). The identification of 
other interacting partners could elucidate the functional role of Ap-2δ. The 
transactivation domain is only poorly conserved among the Ap-2 proteins. A PY motif 
as well as few conserved residues were described to be essential for transactivation 
(Wankhade et al., 2000). Interestingly, Ap-2δ lacks those few conserved PY motif 
and characteristic residues. In an effort to isolate more proteins that interact with Ap-
2δ, a yeast two-hybrid screen was conducted using the unique transactivation 
domain of Ap-2δ as a bait (Markus Moser, Martinsried). Screening of approximately 6 
x 107 clones revealed 38 clones that (i) showed positive interaction after several 
rounds of confirmation and (ii) contained the same reading frame as the vector. Of 
these 38 clones, two clones, Nfatc2 and FoxG1, were especially interesting due to 
their function as transcription factors and were therefore chosen for further analysis. 
The calcium-sensitive Nfatc2 is expressed at relatively high levels in many brain 
compartments including the midbrain and colliculi (Vihma et al., 2008). In neurons, 
Nfatc2 is implicated in synaptic plasticity, axonal outgrowth and neuronal survival 
(Benedito et al., 2005; Graef et al., 1999; Groth and Mermelstein, 2003). FoxG1 is 
expressed in neuronal cells of the telencephalon, in particular the developing dentate 
gyrus and hippocampus (Murphy et al., 1994). In the mouse embryo, expression was 
also detected in the eye, foregut, and otic placode (Huh et al., 1999; Pauley et al., 
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2006). FoxG1 is essential for proper proliferation of the neuronal progenitor 
population (Xuan et al., 1995).  
 
3.2.1. Ap-2δ physically interacts with Nfatc2 and FoxG1  
The interaction of Nfatc2 and FoxG1 with Ap-2δ determined by the yeast two-hybrid 
assay needed to be further verified using other independent methods such as the 
GST pulldown assay. The pull-down assay is an in vitro method used to determine a 
physical interaction between two proteins.  
 
 
 
 
Figure 15: Nfatc2 and FoxG1 physically interact with the transactivation domain of Ap-2δ. GST-
Ap-2δ-TAD or GST alone as negative control were probed for interaction with in vitro translated (i.v.t.) 
Nfatc2 and FoxG1. Interaction was detected via α-HA immunoblotting. Partial (A) and full length (B) 
Nfatc2 as well as full length FoxG1 (C) were retained by GST-Ap-2δ-TAD. Input represent i.v.t. protein 
and serves as a positive control. 10% of the amount used for immunoprecipitation was used for the 
direct detection. 
 
Recombinant fusion proteins consisting of the Ap-2δ transactivation domain (TAD) 
and glutathione S-transferase (GST-Ap-2δ-TAD) or GST control protein (GST) were 
produced. The partial (Nfatc2∆) and full length cDNA fragments of the two potential 
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candidates, Nfatc2 and FoxG1, were N-terminally tagged with an HA epitope and 
cloned into the expression vector pCMX harboring a T7 promoter. GST-Ap-2δ-TAD 
and control GST proteins were incubated with in vitro translated candidate cDNA 
fragments and analysed using SDS-PAGE. Proteins were blotted onto PVDF 
membranes and incubated with α-HA antibody. Partial (Nfatc2∆) and full length 
Nfatc2 as well as full length FoxG1 were retained by GST-Ap-2δ-TAD indicating a 
physical interaction between Ap-2δ and Nfatc2 or FoxG1, respectively (Fig. 15). The 
protein interaction is specifically elicited by Ap-2δ TAD and not the GST portion of the 
fusion protein because GST protein alone does not bind to the potential candidates. 
Nfatc2 was chosen for a more detailed analysis. 
With regard to the sequence identified by the yeast two-hybrid screen, 115 residues of 
Nfatc2 seem to be sufficient for the interaction with the transactivation domain of Ap-
2δ. These residues are located at the C-terminus and partially overlap with the 
conserved Rel homology region that is responsible for DNA binding. 
 
3.2.2. Ap-2δ co-immunoprecipitates with Nfatc2 in vivo 
To analyze if Ap-2δ and Nfatc2 also interact in mammalian cells, full-length Ap-2δ 
and Nfatc2 were transiently expressed in 3T3 cells. Ap-2δ protein was 
immunoprecipitated with α-Ap-2δ antibody from whole cell extracts coupled to 
sepharose beads. To rule out unspecific binding of the protein to the antibody, the 
unrelated GST antibody was also used to immunoprecipitate the co-transfected cell 
extracts. Immunocomplexes were separated in a polyacrylamide gel and detected 
via immunoblotting using an α-HA antibody. Immunocomplexes precipitated with the 
α-Ap-2δ antibody contained Nfatc2, confirming the interaction observed in yeast and 
the in vitro GST pulldown (Fig. 16). In contrast to that, immunoprecipitation with 
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neither the control antibody GST nor in cells transfected with either cDNA alone 
resulted in the isolation of Nfatc2. 
 
 
Figure 16: Interaction between Ap-2δ and Nfatc2 in eukaryotic cells. Proteins from transiently 
transfected 3T3 cells were immunoprecipitated (IP) with α-Ap-2δ antibody and immunoblotted with α-
HA antibody. The partial cDNA fragment of Nfatc2 (HA-Nfatc2∆) was immunoprecipitated with α-Ap-
2δ antibody in Ap-2δ and Nfatc2 cotransfected cells but not in cells transfected with either cDNA 
alone (A). Full length Nfatc2 (HA-Nfatc2 FL) was specifically immunoprecipitated with α-Ap-2δ but not 
a control α-GST antibody (B). Input represents transfected cells before immunoprecipitation and 
serves as a positive control. 10% of the amount used for immunoprecipitation was used for the direct 
detection. 
 
3.2.3. Modulating Nfatc2 activation using Ionomycin and Cyclosporin A 
Nfatc2 was shown to be primarily expressed in the cytoplasm in a highly 
phosphorylated state. Upon several stimuli that raise intracellular calcium levels, the 
calmodulin-dependent phosphatase calcineurin dephosphorylates Nfatc2, unmasks 
a conserved nuclear localization signal and thereby promotes nuclear entry and 
increases DNA binding affinity (Okamura et al., 2000; Okamura et al., 2004). Nfatc2 
dephosphorylation can be facilitated by the addtion of the calcium ionophore 
ionomycin. Ionomycin is  produced by the bacterium Streptomyces conglobatus and 
acts as a motile Ca2+ carrier and enhances Ca2+ influx by direct stimulation of store-
regulated cation entry across biological membranes (Morgan and Jacob, 1994). In 
contrast to that, calcineurin phosphatase activity can be blocked with the help of the 
cyclic hydrophobic decapeptide Cyclosporin A (CsA) derived from the soil funghi 
Tolypocladium inflatum. It has strong immunosuppressive capacity and inhibits the 
  Results 
69 
 
 
dephosphorylation and nuclear entry of Nfatc2. It is highly efficient and displays 
relatively low toxicity. To analyze if transfected Nfatc2 can be activated and 
phosphorylation modulated in 3T3 cells, these cells were treated with either 
ionomycin for 45 minutes or CsA for 5-8 hours. Whole cell or nuclear extracts were 
subjected to SDS-PAGE and immunoblotted using anti-Nfatc2 antibody. Two bands 
were observed in samples treated with ionomycin indicating phosphorylated and 
dephosphorylated Nfatc2. In cells incubated with CsA, only phosphorylated Nfatc2 
can be detected (Fig. 17) indicating a physiological response of the transfected 
Nfatc2 towards the modulating agents.  
 
 
 
Figure 17: Activation of transfected Nfatc2 in 3T3 cells. Whole cell extracts or nuclear extracts 
were prepared from 3T3 cells expressing Nfatc2 and Ap-2δ and stimulated with 0.75 µM ionomycin 
for 1 hour or incubated with the calcineurin inhibitor CsA. Phosphorylation state of Nfatc2 was 
analyzed by western blotting using anti-Nfatc2 antibody. Coomassie stained membrane indicates 
equal loading. p-Nfatc2= phosphorylated Nfatc2. 
 
 
 
3.2.4. Ap-2δ and Nfatc2 co-localize in mammalian cells 
Given that Ap-2δ and Nfatc2 interact in in vitro as well as in vivo experiments, the 
the subcellular distribution of Ap-2δ and Nfatc2 in 3T3 cells was investigated. Under 
the assumption that Ap-2δ and Nfatc2 interact to cooporatively regulate 
transcription, Nfatc2 needs to be present in the nucleus. The subcellular localization 
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of the two proteins was visualized by immunocytochemistry 48 hours after transient 
transfection with full length Ap-2δ and HA-Nfatc2. Under normal growth conditions, 
Ap-2δ was located mainly nuclear whereas Nfatc2 was confined to the cytoplasm 
(Fig. 18, upper panel, DMEM).  
 
 
Figure 18: Co-localization of Ap-2δ and Nfatc2 in 3T3 cells. Expression vector-transfected cells 
were incubated with ionomycin or CsA and visualized by immunofluorescence microscopy after 
double-staining with Ap-2δ and HA antibody and the corresponding secondary antibodies Alexa Fluor 
488 and Alexa Fluor 594, respectively. Scale bar: 50 µm 
 
To modulate Nfatc2 subcellular localization, cells were treated with the calcium 
ionophore ionomycin and the calcineurin inhibitor cyclosporin A (CsA). Ionomycin 
treatment promoted the nuclear entry of Nfatc2 since antibody staining showed an 
even distribution of Nfatc2 throughout the whole cell (Fig. 18, middle panel, 
ionomycin). The inducible nuclear translocation of Nfatc2 was completely abrogated 
by CsA (Fig. 18 bottom panel, Cyclosporin A). 
  Results 
71 
 
 
3.2.5. Identification of target genes regulated by Ap-2δ and Nfatc2 
To gain insights into relevant target genes of both Ap-2δ and Nfatc2, mRNA 
expression of candidate targets was analyzed after ectopic expression of Ap-2δ and 
Nfatc2. Atm, Mtss-1 and c-Fos were already identified as Nfatc2 target genes after 
expression profile analysis of ionomycin-stimulated 8988t pancreas carcinoma cells 
(Manuela Malsy, dissertation, 2009). Atm (ataxia telangiectasia mutated) is a nuclear 
protein that is involved in cell division and DNA repair. Mutations in the Atm gene 
can cause ataxia-telangiectasia, an autosomal recessive disorder, and increase the 
susceptibility to cancer (Lavin and Shiloh, 1996; Thompson et al., 2005). Mtss1 
(metastasis suppressor protein 1) has been reported to play a role as a metastasis 
suppressor in prostate and bladder cancer (Lee et al., 2002; Loberg et al., 2005). C-
Fos is a member of a family of immediate early gene (IEG) transcription factors 
which were also identified as proto-oncogenes. The nuclear phosphoprotein 
functions as a transcriptional regulator of cell proliferation, differentiation, and 
transformation (Piechaczyk and Blanchard, 1994). Egr3 was proposed to be 
regulated by Nfat proteins after the identification of an Nfat regulatory element in the 
Egr3 promoter (Mages et al., 1998). This transcriptional regulator belongs to the 
EGR family of C2H2-type zinc-finger proteins and plays a role in processes including 
muscle development, endothelial cell growth and migration, and neuronal 
development (Kumbrink et al., 2011).  
Nfat proteins are known to interact with other transcription factors that extensively 
determine the selection and regulation of Nfat-controlled genes. Whether these Nfat 
target genes are cooperatively regulated by Nfatc2 and Ap-2δ was investigated by 
qRT-PCR. RNA from Neuro2a cells that were transfected with expression vectors for 
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Ap-2δ and Nfatc2 for 48 hours and incubated with ionomycin for 45 minutes 
analyzed using qRT-PCR on the set of target genes described above. 
 
 
Figure 19: Overexpression of Ap-2δ and Nfatc2 (A) results in reduced expression of target 
genes. Transcript levels of Atm, Egr3, Mtss1 and c-Fos where examined by qRT-PCR after transient 
transfection of Ap-2δ and Nfatc2 expression vectors into Neuro2a cells (B). Gapdh was used as an 
internal control to normalize the expression of each mRNA. Bars are displayed as fold change 
compared to untreated Neuro2a cells and show the mean ± s.e.m. of three independent experiments. 
 
Overexpression of both transcription factors was shown by a potent fold induction, 
ranging from 10.000 - 100.000 fold (Fig. 19A). The downstream targets Atm and 
Egr3 showed residual activity of only 30-40% and Mtss1 retained 50-70% of wildtype 
steady-state transcript levels after overexpression of Ap-2δ and Nfatc2. Co-
transfection of both Ap-2δ and Nfatc2 further substantiate the repression 
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(approximately 30% residual activity). The transcription of c-Fos is merely affected 
showing only a slight induction (Fig. 19B). 
 
3.2.6. Transient siRNA knockdown of Tcfap2d results in upregulation of target 
genes 
SiRNA-mediated transient knockdown of endogenous Tcfap2d was used to study 
consequences on target transcript levels after Tcfap2d downregulation. In this 
process, siRNA molecules bind to and transiently break down the Tcfap2d mRNA, 
thereby inhibiting the translation of the Ap-2δ protein. Untreated cells served as a 
reference for endogenous mRNA and protein levels.  
 
Figure 20: Transient knockdown of Tcfap2d in Neuro2a cells. Neuro2a cells were transfected 
with Tcfap2d siRNA or an unspecific scrambled siRNA (scr control) and analyzed 72 hours later. 
Transcript levels were significantly reduced for 80% in Tcfap2d siRNA-treated cells as indicated by 
qRT-PCR (A). A reduction of Ap-2δ protein was demonstrated by Western blotting. β-actin staining 
was used as loading control. (B). Transfection efficiency was detected with a fluorescence-labeled 
siRNA (C). Scale bar: 500 µm left panel, 200 µm right panel 
 
Transfection efficiency was monitored using a fluorescence-labeled siRNA (Fig. 
20C). Transfection of Neuro2a cells with siRNA was analyzed 72 hours later. The 
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nonsense siRNA did not have any consequence on Tcfap2d mRNA or protein levels. 
In contrast to that, Tcfap2d mRNA levels were significantly reduced for 80% 72 
hours after Tcfap2d siRNA transfection (Fig. 20A). This was further evidenced by 
Western Blot where a strong reduction of Ap-2δ protein was observed (Fig. 20B). 
These data demonstrate the high efficiency of the Tcfap2d siRNA in breaking down 
mRNA levels and preventing protein translation.  
The four genes that had already been analyzed for altered expression after Ap-2δ 
and Nfatc2 overexpression were also examined for expression changes upon 
Tcfap2d knockdown. After Tcfap2d siRNA transfection for 72 hours, RNA was 
collected and cDNA was subjected to qRT-PCR.  
 
Figure 21: Quantitative real-time PCR analysis on candidate target genes after transient 
knockdown of Tcfap2d in Neuro2a cells. RNA from control or Tcfap2d siRNA analyzed for altered 
expression of potential target genes using qRT-PCR. Expression levels were normalized to Gapdh. 
Bars represent fold change of Tcfap2d siRNA-treated samples compared to control siRNA-treated 
samples and show the mean ± s.e.m. of three to six independent experiments. 
 
Atm mRNA was upregulated for more than 4-fold and Egr3 and Mtss1 transcript 
levels were increased 2-3 fold after downregulation of Tcfap2d (Fig. 21). Again, c-
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Fos expression was not altered upon Tcfap2d siRNA transfection. Notably, transcript 
levels of Nfatc2 were also not affected by the downregulation of Tcfap2d. 
 
3.2.7. Atm, Egr3 and Mtss1 are direct targets of Ap-2δ and Nfatc2 
To determine if the observed effects on gene regulation after knockdown or 
exogenous expression of Ap-2δ and Nfatc2 were due to direct binding of these 
transcription factors to the promoters of the candidate target genes, we performed 
chromatin immunoprecipitation in combination with qRT-PCR. This allows mapping 
of the in vivo distribution of chromatin-associated Ap-2δ and Nfatc2. The genomic 
loci of the potential target genes were screened for Ap-2 and Nfat binding sites using 
rVista algorithm (Fig. 22).   
 
 
Figure 22: Schematic presentation of candidate target genomic loci. Potential target genes were 
screened for Ap-2 and Nfat binding sites using rVista algorithm. Ap-2 binding sites are displayed as 
red bars, Nfatc2 binding sites as blue bars. Primers are depicted as arrows. Numbers indicate 
distance relative to TSS. 
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Two regions containing binding sites for either one of the transcription factors or for 
both (Egr3, -2.5 kb) were found in each of the Atm and Egr3 promoters. In the 
genomic locus of Mtss1, four potential sites for the binding of Ap-2δ and Nfatc2 were 
identified (Fig. 22). For all of the eight regions within the three promoters, primers 
were designed to specifically amplify those putative binding sites. Formaldehyde-
fixed chromatin fragments from cotransfected and ionomycin-stimulated Neuro2a 
cells were enriched with antibodies against Ap-2δ and Nfatc2. Immunoprecipitated 
DNA was amplified by qRT-PCR using primer sets flanking the potential Ap-2δ and 
Nfatc2 binding sites.  
The ChIP assay revealed that Ap-2δ occupied the Atm promoter at the two 
previously identified regions. These regions included the sites 80 bp upstream and 
780 bp downstream of the transcriptional start site. In contrast to that, Nfatc2 was 
only enriched at the +780 bp binding site (Fig. 23A). It did not significantly bind to the 
-80 bp region which is only composed of predicted Ap-2 binding sites. Interestingly, 
although the +780 bp locus solely contains Nfat binding sites, Ap-2δ was found to be 
present in this promoter region suggesting physical interaction with Nfatc2. 
Moreover, immunoprecipitation with anti-Ap-2δ antibody revealed high levels of Ap-
2δ at -2.5 kb and -1.9 kb of the Egr3 promoter. Like Ap-2δ, immunoprecipitation with 
the Nfatc2 antibody revealed that Nfatc2 was also associated to both sites (Fig. 
23B). Whereas Nfatc2 did not bind to a region only containing Ap-2 binding sites in 
the Atm promoter, Nfatc2 presence was observed at the -1.9 kb locus of the Egr3 
promoter which only harbors one putative Ap-2 binding site.  
ChIP was also subjected to fragmented chromatin using Ap-2δ and Nfatc2 
antibodies to enrich for either of the four putative binding sites predicted for the 
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Mtss1 promoter. The assay demonstrated a significant level of Ap-2δ binding at all of 
the four sites present in the genomic locus of Mtss1. 
 
Figure 23: In vivo occupancy of Ap-2δ and Nfatc2 at target genomic loci. ChIP/qPCR assays of 
Ap-2δ and Nfatc2-transfected Neuro2a cells. DNA immunoprecipitated with antibodies against Ap-2δ 
and Nfatc2, along with histone H3 or IgG as positive and negative controls was quantified by real-time 
PCR using primers flanking candidate genomic loci. Values were normalized against H3 and 
presented as fold occupancy relative to the negative control IgG. Bars represent fold occupancy ± 
s.e.m. relative to IgG as determined from 4-6 independent experiments. 
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Two of theses sites are located upstream of the TSS (-0.58 kb and -0.34 kb) 
whereas the other two regions were found downstream of the TSS (+0.26 kb and +1 
kb). After DNA fragment enrichment with the Nfatc2 antibody, a substantial Nfatc2 
occupancy could also be observed at regions -0.58 kb, +0.26 kb and +1kb of the 
Mtss1 promoter. Notably, the potential binding site -0.34 kb was not enriched after 
immunoprecipitation with anti-Nfatc2 antibody (Fig. 23C). In the Mtss1 promoter, 
both transcription factors were found to occupy regions which contain potential 
binding sites for both factors (+0.26 kb) as well as regions that only contain binding 
sites for one factor (-0.58 kb and +1kb). 
 
3.2.8. Knockdown of Tcfap2d and withdrawal of Nfatc2 abolish promoter 
occupancy 
To further confirm the promoter occupancy of Ap-2δ and Nfatc2 observed for Atm, 
Egr3 and Mtss1, ChIP was performed on Neuro2a cells that were either depleted of 
Ap-2δ by siRNA or not transfected with an Nfatc2 expression construct. Since Ap-2δ 
and Nfatc2 protein levels are reduced or absent in these cells, respectively, binding 
to the promoter regions of their targets should be reduced. Chromatin fragments of 
these cells were enriched with antibodies against Ap-2δ and Nfatc2. Indeed, 
knockdown of Tcfap2d abolished promoter occupancy at the -80 bp site in the Atm 
promoter and the -1.9 kb site in the Egr3 promoter. Also, enrichment of Ap-2δ at the 
+0.26 kb and +1 kb sites of the Mtss1 promoter was markedly diminished in Tcfap2d 
siRNA-treated cells (Fig. 24 upper panel).  
Notably, Ap-2δ binding to the -2.5 kb region of the Egr3 promoter is only slightly 
reduced in Tcfap2d siRNA-transfected cells indicating unspecific binding to this site. 
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Fig. 24: Knockdown of Ap-2δ and withdrawal of Nfatc2 abolish promoter occupancy. ChIP 
assay and subsequent qRT-PCR of siRNA-transfected (upper panel) or untreated Neuro2a cells 
(lower panel). Immunoprecipitation was performed with Ap-2δ, Nfatc2, H3 and IgG antibodies. Values 
were normalized against H3 and presented as fold occupancy relative to the negative control IgG. 
Bars represent fold occupancy ± s.e.m. relative to IgG as determined from 3 independent 
experiments. 
 
Immunoprecipitation of chromatin fragments from untransfected Neuro2a cells 
compared to Nfatc2-transfected cells with an Nfatc2 antibody revealed smaller 
amounts of enriched DNA from untransfected cells. This was observed at all 
analyzed promoter sites except for the region -80 bp of the Atm promoter (Fig. 24 
lower panel). This is in line with the ChIP assay performed with Nfatc2-transfected 
cells where Nfatc2 binding to this region was not detected (Fig. 23A). In conclusion, 
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the relatively low signals obtained from this site do not seem to be specific and may 
represent background. 
As the -80 bp region of the Atm promoter does not contain any predicted Nfatc2 
binding site but only Ap-2δ binding sites, promoter occupancy by Nfatc2 through 
physical association with Ap-2δ does not seem to occur at this locus. 
In summary, Ap-2δ and Nfatc2 were associated to the gene loci of Atm, Egr3 and 
Mtss1. The differential expression pattern of the target genes upon overexpression 
or downregulation of the transcription factors can therefore be attributed to a direct 
effect exerted by Ap-2δ and Nfatc2.  
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4. Discussion  
4.1. Ap-2δ is a crucial transcriptional regulator of the posterior 
midbrain 
To investigate the role of Ap-2δ in vivo, Tcfap2d-/- mice were generated by 
homologous recombination. New Ap-2δ target genes were identified with the help of 
microarray analysis on brain tissue from control and Ap-2δ-deficient mice. 
Members of the Ap-2 transcription factor family have multiple roles in controlling 
normal growth and differentiation during development. Despite the widespread 
expression of Ap-2α to γ proteins in a variety of different tissues, Ap-2δ expression is 
mainly restricted to the central nervous system, particular to the posterior midbrain. 
The other Ap-2 family members are also co-expressed in the roof of the midbrain. 
However, during embryogenesis, Ap-2δ expression decreases in the anterior 
mesencephalon, becomes enriched in the posterior mesencephalon and 
concentrates in the colliculus inferior. Such a dynamic expression pattern has not yet 
been described for other Ap-2 proteins. Furthermore, expression of the other Ap-2 
isoforms is restricted to the dorsal part of the midbrain leaving Ap-2δ as the only 
expressed isoform in the posterior midbrain at the newborn stage. Thus, Ap-2δ 
seems to be a crucial regulator within this brain structure. Accordingly, ablation of Ap-
2δ in the posterior midbrain results in the complete absence of the Ap-2δ-expressing 
structure of the posterior midbrain, the colliculus inferior, in adult mice. Marker 
analysis of the midbrain/hindbrain region revealed a normal initial organization into 
mid- and hindbrain in Ap-2δ mutant mice although Ap-2δ is already expressed during 
development of this structure (Hesse et al., 2011). These results indicate that 
midbrain/hindbrain organization is controlled either independent from Ap-2δ or due to 
functional redundancy, possibly through compensation by the expression of the other 
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Ap-2 isoforms. However, loss of Ap-2δ in the colliculus inferior of Ap-2δ-deficient 
mice cannot be compensated by other Ap-2 isoforms evidenced by massive 
apoptotic processes on embryonic day E17.  
This phenomenon is in line with other Ap-2 knockout models. All knockout 
phenotypes included apoptotic processes at the main expression sites when 
compensation by other AP-2 proteins was not given indicating their impact on the cell 
survival and maintenance. Ap-2α mutant mice experienced severe cell loss in neural 
structures such as the midbrain, anterior hindbrain and the proximal mesenchyme of 
the first branchial arch (Schorle et al., 1996). The study of Ap-2β-deficient mice 
revealed that downregulation of the anti-apoptotic genes bcl-XL, bcl-w and bcl-2 
occured parallel to massive apoptosis in kidneys of these mice (Moser et al., 1997). 
Finally, inner cell mass outgrowths of Ap-2γ-deficient blastocyst cultures underwent 
differentiation and apototic processes (Werling and Schorle, 2002). A possible 
mechanism for Ap-2-suppressed cell death was proposed by Gaubatz et al. (Gaubatz 
et al., 1995) who demonstrated in an in vitro approach that AP-2 acts as a negative 
regulator of Myc function. AP-2 inhibited Myc transactivation by a direct competition 
for DNA binding and by formation of a ternary Myc/Max/Ap-2 complex which impaired 
DNA binding activity of the Myc/Max complex (Gaubatz et al., 1995). Also, AP-2 can 
modulate apoptosis directly since cotransfection of AP-2α or AP-2β suppressed 
nucleosome release induced by transiently transfected c-myc (Moser et al., 1997). 
These data define a role for AP-2 in negatively controlling myc-induced programmed 
cell death. 
 Ap-2 family members are also involved in cell differentiation by influencing target 
genes transcription. Regulation of the keratin 3 gene transcription by Ap-2 and Sp-1 
determines the differentiation state of rabbit corneal epithelial cells. Differentiation 
and activation of the differentiation-related K3 gene coincided with downregulation of 
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Ap-2 (Chen et al., 1997). Similarly, in a study by Pfisterer et al., Ap-2α was shown to 
repress Klf4 which is implicated in induction of terminal differentiation. Klf4 was 
prematurely expressed in Ap-2α mutant mice and fibroblasts lacking Ap-2α and 
consistently, expressing Klf4 resulted in growth retardation, suggesting that Ap-2α is 
required for cell proliferation by suppression of genes inducing differentiation 
(Pfisterer et al., 2002). 
 
4.1.1. Identification of Ap-2δ target genes in the posterior midbrain 
Since Ap-2δ is essential for the development of the posterior midbrain, this study also 
aimed at the determination of new target genes employing microarray analysis. Using 
this approach, 12 potential downstream targets including four transcription factors 
with a differential expression after Ap-2δ knockout were identified. The expression of 
Pitx2, Mef2c, Bhlhb4 and Pou4f3 in the midbrain was validated with whole mount in 
situ hybridization of wild-type mice. Intriguingly, deletion of Tcfap2d resulted in the 
complete absence of these molecules in this brain structure. These data demonstrate 
that neuronal differentiation is accomplished by expression of several transcription 
factors under the control of Ap-2δ. 
Two genes, Rdh9 and Rgs4, were also upregulated in the absence of Ap-2δ 
suggesting a role for Ap-2δ in gene repression. However, whether Ap-2δ directly 
represses these genes remains to be investigated. Further circumstantial evidence 
for a repressor function of Ap-2 genes comes from reports on Ap-2α-γ repression of 
rat serum amyloid A1 (SAA1) transcription, D(1A) dopamine receptor gene 
transcription and manganese superoxide dismutase (Mn-SOD) expression in a cell-
specific mechanism (Ren and Liao, 2001; Takeuchi et al., 1999; Zhu et al., 2001).  
Primary target genes identified in this study are involved in a number of different 
biological functions including immunoregulation (Slap) and possibly cell migration 
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(Cxcl12). The absence of Ap-2δ furthermore affected genes controlling muscle 
development and contraction (Mef2c, Myh8), signal transduction (Rgs4) and 
metabolism (Ndst4, Rdh9). Interestingly, Pitx2 was found among the genes that 
showed a significant downregulation in the posterior midbrain. Another isoform of 
Pitx2, Pitx2c, is activated by Cited2 and Ap-2α in transient transfections in a 
hepatoma cell line. Moreover, Cited2 and Ap-2α are present at the Pitx2c promoter in 
the heart (Bamforth et al., 2004). Thus, Ap-2α controls Pitx2c expression in the heart 
whereas any Pitx2 isoform may represent a candidate target for Ap-2δ in the brain. 
An important objective of this target gene analysis was to use posterior midbrain 
samples of Ap-2δ-deficient animals representing in vivo expression patterns. This is 
in contrast to previously published work examining Ap-2δ target gene expression 
after exogenous expression or siRNA-mediated knockdown of Ap-2δ in the human 
embryonic kidney cell line AD293 or the neuroblastoma cell line Neuro2a (Sun et al., 
2007; Tan et al., 2009). The approach used here better reflects the in vivo situation 
by avoiding exogenous transfections, however, it is limited to genes expressed in the 
posterior midbrain. Nevertheless, all genes identified on the microarrays were 
validated by qRT-PCR and in situ hybridization. 
 
4.1.2. Transactivation of Bhlhb4 and Pou4f3 by Ap-2δ 
The present study suggests two different mechanisms for Ap-2δ transactivation and 
occupancy of the promoters of Bhlhb4 and Pou4f3. Bhlhb4 is a basic helix-loop-helix 
(bHLH) protein that is expressed in a highly regionalized fashion in the nervous 
system and retina during development and adulthood (Bramblett et al., 2002). Loss 
of Bhlhb4 leads to abolishment of the retinal rod bipolar (RB) cell population. This in 
turn results in disrupted rod signalling and profound retinal dysfunction resembling 
human congenital stationary night blindness (CSNB) (Bramblett et al., 2004). 
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We could not detect a direct binding of Ap-2δ to the Ap-2 binding sites derived from 
the Bhlhb4 promoter. One mechanism for Ap-2δ transactivation would be that Ap-2δ 
associates with and activates the Bhlhb4 promoter through a complex with cofactors 
and interaction partners. Ap-2 proteins have been reported to functionally interact 
with several proteins. Bamforth et al. (Bamforth et al., 2001) showed that Ap-2 
proteins interact with CBP/p300 and mediate Cited2-dependent coactivation. Protein 
interactions of Ap-2 isoforms with other transcription factors were demonstrated for c-
myc, rBP, and p53 (Batsche et al., 1998a; Decary et al., 2002; McPherson et al., 
2002). Recently, Tan et al. provided evidence for a new complex that included Ap-2δ 
associated with Ash2l and Alr which mediated H3K4 trimethylation and gene 
activation of the Hoxc8 locus. It remains to be investigated in which protein complex 
Ap-2δ elicits transactivation of Bhlhb4. 
Pou4f3 is a class IV POU domain transcription factor that is weakly expressed in the 
midbrain, in particular in the inferior colliculus and superior colliculus, and in ganglion 
cells of the retina (Xiang et al., 1995). The expression patterns of Bhlhb4 and Pou4f3 
are almost identical to that of Ap-2δ, supporting our idea that Bhlhb4 and Pou4f3 are 
Ap-2δ target genes. This idea is further substantiated by direct binding of Ap-2δ to a 
defined sequence of the Pou4f3 promoter in a highly specific manner indicated by 
abrogated binding after mutagenesis of the binding site. 
 
4.1.3. Ap-2δ deficiency might result in hearing impairment via Pou4f3 
Pou4f3 is a pivotal regulator of sensorineural development and survival, in particular 
auditory system development. Expression can first be detected in all hair cells of the 
inner ear as soon as they exit cell cycle between E12 and E15 (Xiang et al., 1998).  
Pou4f3-/- inner ears encounter hair cell degeneration resulting in hearing loss. In 
Pou4f3-deficient mice, hair cells initially start to differentiate but undergo apoptosis at 
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embryonic day 17 (Xiang et al., 1998; Xiang et al., 2003). Autosomal dominant 
mutations in the POU4F3 gene have been associated with non-syndromic hearing 
loss DFNA15 in humans (Collin et al., 2008). Since absence of Ap-2δ results in loss 
of the inferior colliculus which is the principal nucleus of the auditory pathway and 
receives input from peripheral brain stem nuclei in the auditory pathway as well as 
from the auditory cortex, it is likely that loss of Ap-2δ leads to a hearing impairment. 
As Ap-2δ expression has not yet been detected in inner ear hair cells, Ap-2δ-
deficient mice are currently investigated for Ap-2δ expression in the ear and a 
concomitant hearing defect. 
Sound is transmitted from the inner ear through the cochlear nuclei and superior 
olivary complex of the brainstem towards the inferior colliculus. In the inferior 
colliculus, sound information is integrated and then transferred to the medial 
geniculate nucleus (MGB) of the thalamus. It acts as a thalamic relay station that 
further processes auditory signals before they are received by the auditory cortex. 
Interestingly, mice already harbor these auditory connections before acquiring 
hearing. This suggests that formation of auditory connections is genetically anchored 
(Gurung and Fritzsch, 2004). First results from electrophysiological recordings of 
neocortical neurons suggest that Ap-2δ mutant mice are indeed able to respond to 
sound indicated by tone-evoked neuronal responses at the neocortical level (Hesse 
et al., 2011). Therefore, a compensatory mechanism seems to have evolved that 
overcomes the need for a colliculus inferior and adopts its function. An alternative 
pathway omitting the inferior colliculus was identified in bats and cats (Casseday et 
al., 1989). Fibers originating in the nucleus of the central acoustic tract (NCAT) 
travelled ventral to the inferior colliculus and medial and ventral to the brachium of 
the colliculus inferior. Via these pathways, auditory information can reach the deep 
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superior colliculus and the suprageniculate nucleus along cortical and subcortical 
routes bypassing the colliculus inferior (Casseday et al., 1989; Kobler et al., 1987). 
This proposed pathway may provide a route for individual tones that arouse cortical 
neuronal activity in Ap-2δ-deficient mice. It is therefore interesting to analyze the 
response to more complex processing tasks in the absence of the inferior colliculus. 
Accordingly, auditory discrimination learning tests should be employed to investigate 
learning performance. Preliminary data of this kind of test revealed that mice lacking 
Ap-2δ were able to to learn the discrimination of tones and showed a significant 
performance level. Nevertheless, learning speed was much slower and took five days 
longer to reach significant discrimination compared to a large sample of normal 
hearing NMRI mice (Kurt & Ehret, unpublished data). Thus it seems that at least 
some auditory discrimination capability is preserved in Ap-2δ-/- mice despite absence 
of a functional inferior colliculus. Further studies will be necessary to contribute to 
clarification of these mechanisms (Kurt and Ehret, in progess). 
 
Ap-2δ-mediated acvtivation of Pou4f3 can also occur in the midbrain or the retina, but 
the function of Pou4f3 in the midbrain is not clear to date. A prominent phenotype of 
reduced Pou4f3 expression due to loss of Ap-2δ in the retina is not very likely since 
targeted Pou4f3 disruption does not cause retinal defects probably due to a 
functional compensation by Pou4f2 (Erkman et al., 1996; McEvilly et al., 1996; Xiang 
et al., 1997). 
In summary, this study demonstrates that Ap-2δ is a central, higher-order 
transcription factor that establishes the survival and maintenance of posterior 
midbrain cells by suppressing apoptosis. Ap-2δ ablation results in massive apoptotic 
processes eventually leading to the loss of the colliculus inferior. Control of midbrain 
development by Ap-2δ can further be substantiated by the identification of Bhlhb4 
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and Pou4f3 along with a set of other candidates from the posterior midbrain as de 
novo Ap-2δ target genes. Thus, the data presented here provide new insights into 
the molecular mechanisms underlying posterior midbrain development governed by 
Ap-2δ. 
  Discussion 
90 
4.2. Transcription factors Ap-2δ and Nfatc2 interact to 
synergistically regulate target gene transcription 
4.2.1. Identification of FoxG1 and Nfatc2 as binding partners for Ap-2δ  
In a previous study, potential interacting partners of Ap-2δ were isolated using the 
yeast two-hybrid system to gain insights into the biological function of Ap-2δ. The Ap-
2δ transactivation domain served as a bait protein that was screened against an 
adult mouse brain cDNA library (prey). After verification by retransformation, X-gal 
filter assays, autoactivity screens, and sequencing of the cDNAs, the number 
potential interactors was narrowed down to 38 candidates. FoxG1 and Nfatc2 were of 
special interest due to their function as transcription factors because Ap-2 proteins 
have been reported to exert their function by interaction with other transcription 
factors (Wu and Lee, 2001). In this study, verification of the yeast two-hybrid assay 
was initially performed with both candidates. FoxG1 is a winged helix transcription 
factor expressed in the telencephalon, retina, optic stalks, otic placode, and superior 
colliculus (Hebert and McConnell, 2000; Xuan et al., 1995). FoxG1-Cre mice that 
express Cre under the control of FoxG1 regulatory elements also confer 
recombination in the ear, olfactory epithelium, the mid-hindbrain junction, and facial 
and head ectoderm (Hebert and McConnell, 2000). 
Since the partial FoxG1 fragment obtained from the screen was not retained by GST-
Ap-2δ-TAD in the GST pulldown assay, the interaction between Nfatc2 and Ap-2δ 
was examined in more detail. 
 
The in vitro GST pulldown assay demonstrated that the Ap-2δ-Nfatc2 interaction is 
mediated via the TAD of Ap-2δ and the DNA binding and C-terminal regions of 
Nfatc2. Co-immunoprecipitation assays furthermore showed that the interaction 
occured in vivo and also confirmed interaction in mammalian cells. The physiological 
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basis of this interaction was demonstrated by co-localization of both proteins in the 
nucleus after activation of Nfatc2.  
Nfatc2 is a member of the Nfat family that are expressed at relatively high levels in 
many brain compartments (Vihma et al., 2008). Expression increases during 
postnatal development and is most abundant in the colliculi, cerebellum, medulla, 
olfactory bulb and striatum. Interestingly, Nfatc2 is the predominantly expressed 
isoform in the mouse brain. Its mRNA is widely expressed at high or moderate levels 
in most cells of the thalamus, hypothalamus, and midbrain. In contrast, Nfatc1, 
Nfatc3, and Nfatc4 are not significantly expressed in these brain structures. This 
partially overlapping expression pattern of Nfatc2 with Ap-2δ constitutes a 
prerequisite for the physiological interaction.  
  
4.2.2. Interaction of Ap-2δ and Nfatc2 in regulation of target genes 
In neurons, Nfat is implicated in synaptic plasticity, axonal outgrowth and neuronal 
survival (Benedito et al., 2005; Graef et al., 1999; Groth and Mermelstein, 2003). It is 
believed that different neuronal subtypes may use distinct Nfat transcriptional 
complexes to elicit morphogenic or pro-survival signals.  
Nfat function is orchestrated by the formation of regulatory complexes with other 
transcription factors (Macian, 2005). Those complexes are not only characterized by 
their functional synergy but also by cooperative physical interaction between two or 
more transcription factors that bind to DNA. The cooperative regulation of Atm, Egr3, 
and Mtss1 by Ap-2δ and Nfatc2 was analyzed by qRT-PCR and ChIP assays and 
demonstrates that Ap-2δ and Nfatc2 negatively regulate these targets by binding to 
their promoters in vivo. Various binding sites for Ap-2 and Nfat in the promoters of the 
candidate targets were proposed by the algorithm rVista. These binding sites were 
neither overlapping nor in close proximity to each other, thereby excluding the 
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mechanism of physical interaction after binding to the factor-specific sites reported in 
the above mentioned studies. Here, Ap-2δ and Nfatc2 did not only bind to their 
specific putative binding sites but were also found at promoter regions only 
containing binding sites for the interaction partner (Fig. 25).  
 
 
Fig. 25: Model for promoter occupancy of Ap-2δ and Nfatc2. Ap-2δ and Nfatc2 can either bind to 
their own specific putative binding sites (Mtss1 +0.26kb) or they occupy genomic loci containing only 
binding sites for one of the two factors by physical interaction (Egr3 -1.9kb and Mtss1 +1kb). 
 
Therefore, Ap-2δ and Nfatc2 are able to exert their regulatory potential by occupancy 
at the target promoter through physical interaction with their partner. This has already 
been reported for AP-2α as well as for NFATc2. The interaction of AP-2α and YY1 in 
the hamster histone H3.2 gene occurs through binding to sequences specific for 
each factor as well as through binding in a complex to only AP-2 specific sites (Wu 
and Lee, 2001). The idea that direct binding of NFAT to DNA might be dispensable 
and can be replaced by interaction with other transcription factors was proposed in 
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studies with SP-1 and NFATc2. Calcineurin upregulates SP-1-dependent 
transcription of p21 promoter activity by association of NFAT with SP-1 (Santini et al., 
2001).  
 
4.2.3. Ap-2δ and Nfat2c-regulated genes in the nervous system 
Since target genes of Nfat proteins have been primarily determined outside the 
nervous system, only little is known about genes under the control of the calcineurin-
Nfat-signaling in the nervous system. IP3R1, Bdnf, CCR2 and Cox-2 are genes that 
have been described to be regulated by Nfat proteins in the nervous system. (Graef 
et al., 1999; Groth et al., 2007; Groth and Mermelstein, 2003; Jung and Miller, 2008). 
This study demonstrates for the first time new target genes of the nervous system 
that are regulated by both Ap-2δ and Nfatc2. The findings presented here provide 
evidence that the widely expressed Nfatc2 transcription factor interacts with the 
highly restricted and neuronal-specific transcription factor Ap-2δ thereby involving 
Nfatc2 in the regulation of neuronal target gene transcription. This interaction may 
direct Nfat-dependent gene expression in neurons and achieve specificity of Nfat 
proteins despite their almost ubiquitous expression pattern. Moreover, the results of 
this study implicate that Ap-2δ and Nfatc2 combinatorially regulate gene expression 
in a negative manner (Fig. 22). Atm, Egr3, and Mtts1 were downregulated upon 
overexpression of Ap-2δ or exogenous expression of Nfatc2 in Neuro2a cells. Owing 
to the concerted interaction, this effect was enhanced when expression plasmids of 
both transcription factors were transfected. Accordingly, knockdown of Ap-2δ by 
siRNA resulted in increased target mRNA transcripts.  
This is the first work demonstrating a repressive function for the transcription factor 
Ap-2δ. It was suggested before that Ap-2δ might utilize an alternative mechanism for 
transactivation or might act as a repressor due to its divergent TAD (Zhao et al., 
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2001). Moreover, the microarray performed in the first part of this study identified the 
two genes Rdh9 and Rgs4 that were upregulated in the absence of Ap-2δ, already 
suggesting a role for Ap-2δ in gene repression (see page 84). This study now 
provides evidence that Ap-2δ indeed has the potential to repress target gene 
transcription. The repressive effect is not only elicited by interaction with Nfatc2 since 
overexpression of Ap-2δ alone already confers reduced transcript levels of target 
genes.  
 
4.2.4. The serine/threonine protein kinase Atm 
Atm participates in orchestrating cell cycle in response to DNA damage and oxidative 
stress (Rotman and Shiloh, 1997a, 1997b; Watters, 2003). Mutational loss of Atm 
contributes to ataxia-telangiectasia (A-T), a disease characterized by progressive 
neurodegeneration, radiosensitivity, cell-cycle checkpoint defects, genome instability, 
and a predisposition to cancer (Kastan and Lim, 2000; Lavin and Shiloh, 1996). One 
of the earliest cellular phenotypes discovered was a defect in cell cycle control. The 
efficient induction of the tumor suppressor p53 in the G1/S cell cycle checkpoint 
following irradiation depends on Atm (Kastan et al., 1992). Atm phosphorylates p53 
and its interactors MDM2 and Chk2, thereby allowing p53 to activate its target genes, 
particularly the cyclin-dependent kinase (CDK) inhibitor p21 which results in the 
inhibition of cyclin-E/CDK2 complex and inhibition of progression from G1 into S-
phase (Kastan and Lim, 2000).  
The downregulation of a DNA repair and cell cycle checkpoint protein does not seem 
to be desirable during development in a highly proliferative environment in which 
mutations can have a major impact. On the other hand, high amounts of Atm result in 
cell cycle arrest and eventually cell death. The Ap-2δ and Nfatc2-mediated 
downregulation of Atm could reduce phosphorylation of p53 and downstream targets 
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to promote cellular proliferation. A recent study reported that Atm-depletion in a 
human neural stem cell line ihNSC did not affect growth rate, DNA replication or 
chromosomal stability (Carlessi et al., 2009). However, it attenuated the response to 
IR-induced DNA damage. When Atm-depleted ihNSCs were subjected to 
differentiation, similar numbers of neurons and astrocytes were found in control and 
shATM cells. The number of oligodendrocytes was mildly reduced. These data 
suggest a dispensable role for Atm during differentiation of ihNSCs toward the 
neuron and astrocyte lineage. Interestingly, the authors observed a substantial 
increase in apoptotic markers such as cleaved caspase 3 and 9 and an accumulation 
of p53 and p21waf1 accompanying the differentiation of ihNSCs. This apoptotic activity 
was less pronounced in Atm-depleted cells (Carlessi et al., 2009). Maric et al. (Maric 
et al., 2007) already reported that during early neurogenesis, neural stem cells 
encounter both lineage differentiation and apopotosis. Ap-2δ and Nfatc2-conferred 
downregulation of Atm might therefore repress apoptotic activity. This is in line with 
the phenotype of Ap-2δ-/- mice described in the first part of this work. Knockout of 
Ap-2δ resulted in increased apoptosis of posterior midbrains. The absence of Ap-2δ 
could relieve Atm repression which in turn could activate p53 and downstream 
signaling to elicit cell death. This hypothesis is supported by the finding presented in 
this study that knockdown of Ap-2δ in Neuro2a cells led to upregulation of Atm 
transcription. Further work is needed to analyze phosphorylation states of Atm, p53 
and downstream targets like p21 in Ap-2δ-/- mice to confirm this hypothesis.  
Controversial data were reported by Kim and Wong (Kim and Wong, 2009). Owing to 
the progressive neurodegeneration as one of the main phenotypes of A-T, the 
authors investigated the effects of Atm loss on murine neural stem cells (NSC). 
Cultured subventricular zone neurospheres from Atm-deficient mice showed impaired 
proliferation. Several signaling pathways seemed to be affected as Akt and Erk1/2 
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pathways were disrupted and the p38 mitogen-activated protein kinase (MAPK) 
activity was enhanced. These findings suggest that Atm plays a crucial role in NSC 
proliferation by activating Akt and Erk1/2 pathways and suppressing p38 MAPK 
signaling (Kim and Wong, 2009). Whether these pathways are also affected after Ap-
2δ and Nfatc2-mediated repression of Atm stills needs to be investigated. 
 
4.2.5. The early growth response transcription factor Egr3 
Early growth response (Egr) transcription factors belong to the regulatory immediate 
early genes that are expressed in response to neuronal activity coupled to MAPK-Erk 
signaling. Egr1 and Egr3 are the most abundant Egr proteins upregulated by synaptic 
activity in the brain (Li et al., 2005; O'Donovan and Baraban, 1999). These NMDA 
receptor/MAPK-Erk signaling molecules may modulate target gene expression 
required for long-term structural and physiological synaptic changes associated with 
learning and memory. In support of this, CA-1 hippocampal neurons of Egr-deficient 
mice show abnormal long-term potentiation. Accordingly, Egr-/- mice display 
profound impairments in context and cued-associated learning and short-term and 
long-term objective recognition memory (Li et al., 2007).  
Studies on the molecular basis of learning and memory have highlighted the impact 
of calcium-regulated pathways (reviewed in Platenik et al., 2000). Nfatc4 has also 
been implicated in learning and memory as it regulates IP3R1 expression in 
hippocampal neurons. This regulation may be important for synaptic plasticity and 
long-term depression (Graef et al., 1999). Further evidence for a role of Nfat in 
memory was given by de la Fuente (de la Fuente et al., 2011). Hippocampal 
calcineurin induced nuclear Nfat translocation after a prolonged re-exposure to the 
training context of fear conditioning. This activation resulted in memory extinction. 
Also, TNF-a was described to be activated by calcineurin/Nfat signaling. TNF-a has 
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been proposed to be involved in the pathogenesis of neurodegenerative diseases 
related to memory (Elliott, 2001; Ghezzi et al., 1998) and TNF-a knockout mice 
display deficits in spatial learning and memory (Golan et al., 2004). These findings 
assign a role for calcineurin/nfat signaling in learning and memory. The observation 
that Ap-2δ and Nfatc2 regulate Egr3 expression may further contribute to the 
understanding of the molecular basis of learning and memory. Interestingly, Ap-2δ-
deficient mice subjected to auditory discrimination learning tests showed a delayed 
learning behavior compared to normal-hearing mice, indicating that Ap-2δ 
downstream signaling is indeed involved in learning and memory. 
 
4.2.6. The metastasis suppressor protein Mtss1 
The metastasis suppressor protein 1 (Mtss1; also called “missing in metastasis” 
(MIM)) was originally identified as a potential metastasis suppressor as the transcript 
was missing in metastatic bladder and prostate cancer (Lee et al., 2002). It is 
suggested to have a scaffolding function although its in vivo role is not yet fully 
understood. Mtss1 was identified as a transcriptional co-factor in association with the 
sonic hedgehog (Shh) signaling pathway. Mtss1 cooperates with and co-activates the 
transcription factor Gli-1 and Gli-2 to potentiate the activation of the Shh 
transcriptional pathway in epidermal cells. The identification of conserved nuclear 
localization signals and a nuclear export signal emphasizes the dual role of Mtss1 in 
cytoskeleton remodelling and transcriptional regulation (Glassmann et al., 2007). 
Mtss1 has been observed to be downregulated or missing in several cancer cells 
compared to normal tissue. Mtss1 transcript levels were found to be downregulated 
in prostate cancer cell lines such as PC-3, Du145 and LNCap cells as well as in 
patient samples of benign prostate hyperplasia, localized prostate cancer and 
metastatic prostate cancer (Loberg et al., 2005). Accordingly, overexpression of 
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Mtss1 suppressed growth of transformed and cancer cell lines (Utikal et al., 2006). 
These findings, together with the implication in Shh signaling, indicate an important 
role for Mtss1 in tumor development. 
In a very recent study, Mtss1 was reported to be required for neural fold elevation 
and anterior neural tube closure in Xenopus laevis. Mtss1 depletion inhibited anterior 
neural fold closure without affecting anterior gene expression. In particular, Mtss1 
specifically binds to Daam1 and mediates non-canonical Wnt signaling. Thus, Mtss1 
provides a link between non-canonical Wnt signaling and the remodeling of the actin 
cytoskeleton and changes in membrane dynamics required for neural tube closure 
(Liu et al.). Similarly, Ap-2α knockout mice also suffer from a failure in neural tube 
closure (Schorle et al., 1996; Zhang et al., 1996). These data together with the 
findings of this work that Ap-2δ and Nfatc2 influence Mtss1 transcription support the 
idea that Ap-2 proteins and Mtss1 may eventually converge upon the same 
developmental regulatory pathways. 
 
In summary, this work demonstrates that Ap-2δ and Nfatc2 specifically interact with 
each other. The physical interaction is mediated via the TAD of Ap-2δ and the DNA 
binding and C-terminal region of Nfatc2. This interaction augments in synergistically 
regulating expression of the newly identified targets Atm, Egr3, and Mtss1. 
Furthermore, this study for the first time provides evidence for a repressive function 
of Ap-2δ.  Atm, Egr3, and Mtss1 were shown to be repressed by Ap-2δ and Nfatc2 
(Fig. 26). Thus, these data provide insights into the complex transcriptional network 
in neurons in which Ap-2δ and Nfatc2 participate.  
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Figure 26: Model for target gene regulation by Ap-2δ and Nfatc2 in neurons. Nfat nuclear 
translocation in neurons can be elicited by a number of stimuli. Membrane depolarization opens L-type 
voltage gated calcium channels (L-VGCC). An initial Ca
2+
 release can also be triggered by L-type 
calcium channels (LGCC), NMDA receptors, neurotrophin binding to TrK receptors, and netrin/DCC 
signaling. Upon dephosphorylation by calcineurin (Cn), Nfat enters the nucleus and associates with 
binding partners. Nuclear entry is counteracted by a number of kinases including GSK-3, CK-1, 
DYRK1, and DYRK2 and calcineurin inhibitors CsA and FK506. This study demonstrates that Nfatc2 
interacts with Ap-2δ to synergistically regulate target genes. Atm, Egr3, and Mtss1 were identified as 
new target genes negatively regulated by both transcription factors.   
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4.3. Outlook 
The function of transcription factor Ap-2δ is only poorly understood. In an effort to 
elucidate the role of Ap-2δ, the Tcfap2d gene was inactivated in mice. Knockout of 
Tcfap2d resulted in loss of the colliculus inferior, the principal nucleus for auditory 
input. Thus, Ap-2δ null mice serve as a model system to study hearing. First 
evidence from electrophysiological recordings suggest that Ap-2δ-deficient mice are 
able to respond to sound but show delayed learning behavior. Therefore, Ap-2δ 
expression in the ear and hearing ability of Ap-2δ mutant mice should be analyzed in 
depth. Experiments such as electrophysiological recordings as well as tracing studies 
have to be performed in order to analyze how auditory information reaches the 
neocortex in these animals. Emphasis should be put on more complex processing 
tasks involving learning and memory such as auditory discrimination learning tests. 
In this context, involvement of regulation of Egr3 transcription by Ap-2δ and Nfatc2 
should also be taken into account. Since both Egr3 and Nfatc2 have been reported to 
play important roles during learning and memory processes, the contribution of these 
two factors to the delayed learning process in Ap-2δ mutant mice should be 
considered. 
Another interesting approach would be the investigation of Ap-2δ in the 
diencephalon. Expression analysis revealed that the main expression locus of Ap-2δ 
is the posterior midbrain. Nevertheless, the transcription factor is also expressed in 
the diencephalon, possibly the medial geniculate body (MGB), at moderate levels. As 
described before, the MGB receives input from the inferior colliculus and sends 
projections to the auditory cortex. It would therefore be attractive to study 
thalamocortical connections in Ap-2δ knockout mice using tracing experiments. 
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The interaction and regulation of target genes by Ap-2δ and Nfatc2 were 
demonstrated in this study. To gain further insights into the mode of interaction 
between these two transcription factors, the influence of interaction can be 
investigated using luciferase assays on co-transfected cells. With the help of these 
assays, the impact of Ap-2δ or Nfatc2 to increase the regulatory potential of its 
interacting partner can be elucidated. Furthermore, other isoforms of Ap-2 and Nfat 
proteins can be tested for their ability to interact. This might determine whether Ap-2 
proteins are general binding partners for Nfat proteins or whether Ap-2δ and Nfatc2 
interact specifically.  In this context, mutants of both proteins might identify the exact 
interaction domain. 
To identify other target genes synergistically activated or repressed by Ap-2δ and 
Nfatc2, a microarray approach would be useful. The microarray could be performed 
with RNA from cells overexpressing Ap-2δ and Nfatc2 or alternatively, with RNA 
depleted of both transcription factors by a siRNA approach.  
To further understand the regulatory mechanism exerted by Ap-2δ and Nfatc2, the 
signaling cascade elicited after repression of the here identified target genes could 
be investigated. For example, Atm is repsonsible for the activation of p53, MDM2 and 
Chk2. Therefore, the phosphorylation states of Atm, p53 and other downstream 
targets like p21 should be analyzed in Ap-2δ-/- mice. Moreover, Atm-deficient NSCs 
showed impaired proliferation due to disrupted Akt and Erk1/2 pathways and 
enhanced p38 MAPK signaling (Kim and Wong, 2009). It would be interesting to find 
out whether these pathways are also affected in cells with reduced Atm transcript 
levels mediated by Ap-2δ and Nfatc2. 
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